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Editorial, see p 260
BACKGROUND: Reduction in cardiovascular death and hospitalization 
for heart failure (HHF) was recently reported with the sodium-glucose 
cotransporter-2 inhibitor (SGLT-2i) empagliflozin in patients with type 2 
diabetes mellitus who have atherosclerotic cardiovascular disease. We 
compared HHF and death in patients newly initiated on any SGLT-2i versus 
other glucose-lowering drugs in 6 countries to determine if these benefits are 
seen in real-world practice and across SGLT-2i class.
METHODS: Data were collected via medical claims, primary care/hospital 
records, and national registries from the United States, Norway, Denmark, 
Sweden, Germany, and the United Kingdom. Propensity score for SGLT-2i 
initiation was used to match treatment groups. Hazard ratios for HHF, death, 
and their combination were estimated by country and pooled to determine 
weighted effect size. Death data were not available for Germany.
RESULTS: After propensity matching, there were 309 056 patients newly 
initiated on either SGLT-2i or other glucose-lowering drugs (154 528 patients 
in each treatment group). Canagliflozin, dapagliflozin, and empagliflozin 
accounted for 53%, 42%, and 5% of the total exposure time in the SGLT-2i  
class, respectively. Baseline characteristics were balanced between the 2 
groups. There were 961 HHF cases during 190 164 person-years follow-up 
(incidence rate, 0.51/100 person-years). Of 215 622 patients in the United 
States, Norway, Denmark, Sweden, and the United Kingdom, death occurred 
in 1334 (incidence rate, 0.87/100 person-years), and HHF or death in 1983 
(incidence rate, 1.38/100 person-years). Use of SGLT-2i, versus other glucose-
lowering drugs, was associated with lower rates of HHF (hazard ratio, 0.61; 
95% confidence interval, 0.51–0.73; P<0.001); death (hazard ratio, 0.49; 
95% confidence interval, 0.41–0.57; P<0.001); and HHF or death (hazard 
ratio, 0.54; 95% confidence interval, 0.48–0.60; P<0.001) with no significant 
heterogeneity by country.
CONCLUSIONS: In this large multinational study, treatment with SGLT-2i 
versus other glucose-lowering drugs was associated with a lower risk of 
HHF and death, suggesting that the benefits seen with empagliflozin in a 
randomized trial may be a class effect applicable to a broad population of 
patients with type 2 diabetes mellitus in real-world practice.
CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique 
identifier: NCT02993614. 
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Type 2 diabetes mellitus (T2D) remains a major risk factor for cardiovascular disease (CVD)1,2 and overall mortality,3,4 despite advances in treatment.5–7 Heart 
failure is an especially common complication of T2D,8–10 
with particularly poor outcomes and 5-year survival 
rates of <25%.11 This highlights the need for novel 
treatments that not only improve glycemic control, but 
also reduce the risk of CVD, including heart failure.
Although higher hemoglobin A1c is associated with 
greater risk of CVD,12 intensive glucose control has 
failed to reduce the development of heart failure, and 
cardiovascular-related or all-cause death. However, the 
EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] 
Cardiovascular Outcome Event Trial in Type 2 Diabetes 
Mellitus Patients), a prospective randomized controlled 
trial in patients with T2D and established atheroscle-
rotic CVD, demonstrated a substantial reduction in car-
diovascular death and hospitalization for heart failure 
(HHF) with the sodium-glucose cotransporter-2 inhibi-
tor (SGLT-2i), empagliflozin,13 within a short follow-up 
period. The mechanisms of these benefits, although un-
clear, were almost certainly not attributable to glucose 
lowering, given a very small difference in hemoglobin 
A1c levels between empagliflozin- and placebo-treated 
patients and early separation of the event curves.
Following the EMPA-REG OUTCOMES trial, several 
critical questions remain, with substantial clinical implica-
tions. First, the applicability of findings to real-world clini-
cal practice (where patients receive standard of care with 
various other glucose-lowering drugs [oGLDs]) is unclear. 
Second, it is unknown whether the observed benefits 
are specific to empagliflozin, or represent a class effect. 
Finally, because EMPA-REG OUTCOME only included pa-
tients with established CVD, it remains to be seen if simi-
lar benefits can be expected in patients with T2D who 
have a broader cardiovascular risk profile.
Using data from multiple countries in the CVD-
REAL study (Comparative Effectiveness of Cardiovas-
cular Outcomes in New Users of SGLT-2 Inhibitors: 
NCT02993614), we compared the risk for HHF, death, 
and the combined end point of HHF or death in pa-
tients with T2D who were new users of SGLT-2i versus 
oGLDs in real-world practice.
METHODS
Data Sources
Deidentified health records across 6 countries (United States, 
Germany, Sweden, Norway, Denmark, and the United 
Kingdom) were analyzed. In the United States, Truven Health 
MarketScan Claims and Encounters and linked Medicare 
Supplemental and Coordination of Benefits databases were 
used, which included enrollment and demographic informa-
tion, inpatient and outpatient medical, and outpatient phar-
macy claims from >300 large self-insured US employers and 
>25 US health plans. In Germany, the Diabetes Prospective 
Follow-Up initiative is a quality assessment registry for individ-
uals with diabetes mellitus and uses standardized documen-
tation and objective comparison of quality indicators, with 
452 centers participating. In Sweden, Norway, and Denmark, 
mandatory national full-population registries of each respec-
tive country were used, with linked Prescribed Drug Registers 
covering all drugs dispensed, National Patient Registers cover-
ing all hospitalizations and specialized outpatient care, and 
Cause of Death Registers.14–17 In the United Kingdom, records 
from the Clinical Practice Research Datalink and The Health 
Improvement Network data sets were used, which included 
primary care data from >670 general practices linked with 
hospitalization and mortality registries. Additional details of 
the individual data sets can be found in the online-only Data 
Supplement Appendix.
Patient Cohort
Patients with T2D (diagnosis codes in online-only Data 
Supplement Tables I and II) who were newly started on either 
SGLT-2i or oGLDs were selected from each data set beginning 
on the date of first prescription or pharmacy dispensation 
Clinical Perspective
What Is New?
• This is the first large real-world study of >300 000 
patients with type 2 diabetes mellitus, both with 
and without established cardiovascular disease, 
from routine clinical practice across 6 countries, 
evaluating the outcomes of hospitalization for 
heart failure (HHF) and all-cause death in patients 
with type 2 diabetes mellitus treated with sodium-
glucose cotransporter-2 inhibitors (SGLT-2i) versus 
other glucose-lowering drugs.
• The distribution of exposure time for the various 
SGLT-2i compounds (for HHF outcome) was 53% 
for canagliflozin, 42% for dapagliflozin, and ≈5% 
for empagliflozin, with substantial intercountry 
variability.
What Are the Clinical Implications?
• Treatment with SGLT-2i versus other glucose-lower-
ing drugs was associated with a 39% relative risk 
reduction in HHF, a 51% reduction in all-cause death, 
and a 46% reduction in the HHF or death composite, 
consistent with the effects previously reported in a 
randomized clinical trial of empagliflozin.
• Approximately 87% of patients did not have 
known cardiovascular disease, suggesting possible 
cardiovascular benefits for a broad population of 
patients with type 2 diabetes mellitus.
• The lower rates of HHF and death associated with 
SGLT-2i treatment are likely class related, as there 
was no significant heterogeneity across countries, 
despite geographic variations in the use of specific 
SGLT-2i (≈76% canagliflozin in the United States 
and ≈92% dapagliflozin in Europe).
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of an SGLT-2i or a new oGLD in each of the countries (start 
date ranged from November 2012 in the United Kingdom to 
July 2013 in Sweden). New users were defined as individuals 
prescribed/filling a prescription (as initial or add-on therapy) 
for any SGLT-2i (canagliflozin, dapagliflozin, or empagliflozin) 
or oGLD (any other oral or injectable medication), including 
fixed-dose combinations, with no issued prescriptions of that 
medicine class during the preceding year (in Germany, with no 
prior documentation in the medical record of using that medi-
cine class within the previous 6 months). Additional inclusion 
criteria were age ≥18 years on the index date (defined as the 
prescription date for new SGLT-2i or new oGLD), and >1 year 
data history in the database before the index date. Patients 
with type 1 or gestational diabetes were excluded. Patients 
were followed from the index date until the end of the index 
treatment (for the on-treatment analysis), migration/leaving 
the practice/database, last date of data collection, outcome 
date, or censoring date (range from September 2015 in the 
United States to November 2016 in Sweden).
Outcomes
Primary outcome was HHF assessed in all countries. In the 
United States, United Kingdom, and Germany, HHF was 
defined as hospital admissions for heart failure (defined using 
primary discharge diagnosis codes in the United States,18 pri-
mary discharge diagnosis codes and documentation from the 
electronic health records in the United Kingdom, as defined in 
the online-only Data Supplement Appendix, and documenta-
tion in the electronic health records in Germany). In the Nordic 
countries (Sweden, Norway, and Denmark), HHF was defined 
by any hospital visit, in- or outpatient (ie, prognostically equiv-
alent outpatient heart failure [HF] event),19 with a registered 
primary diagnosis of HF (defined using diagnosis codes for 
HF events as detailed in the online-only Data Supplement 
Appendix, and validated independently in all 3 countries).20–22 
Secondary outcomes included all-cause death, and a compos-
ite of HHF or all-cause death (time-to-first-event), evaluated in 
all countries, except Germany. In the United States, all-cause 
death was identified by using the MarketScan Mortality File 
in which information from the Social Security Administration 
is integrated with the insurance enrollment and claims data, 
supplemented by claims for in-hospital deaths, covering 
≈61% of the overall US-based propensity-matched patient 
cohort. Characteristics of US patients with and without vital 
status were similar (online-only Data Supplement Table III), 
indicating data missing completely at random because of 
administrative reasons.
Statistical Analysis
Baseline characteristics of patients in the SGLT-2i and 
oGLD groups were analyzed by using descriptive statistics. 
Categorical variables were described by frequencies and per-
centages, and continuous variables by using mean (± SD). For 
continuous variables such as age, the overall mean across all 
databases was a summary estimate of country-specific means, 
weighted according to the number of patients in each respec-
tive database.
For the SGLT-2i group, the percentage of individual agents 
and their respective contributions to the overall SGLT-2i 
exposure time, and for the oGLD group, the percentage of 
individual drug classes, were summarized by country/geo-
graphic region and overall.
A nonparsimonious propensity score was developed (sepa-
rately within each country) for being initiated on an SGLT-2i 
to minimize confounding. Variables that may have affected 
treatment assignment or outcomes were included in the pro-
pensity score (online-only Data Supplement Table IV).23 Based 
on propensity scores, patients receiving SGLT-2i were matched 
1:1 with those receiving oGLDs. Nearest-neighbor caliper 
width of 0.25 multiplied by the SD of the propensity score 
distribution was used for the matching.23 In Sweden, Norway, 
and Denmark, an automated balance optimization method 
using the function Match (in package Matching) in R and a 
caliper of 0.2 were used for matching. The adequacy of pro-
pensity matching was assessed by standardized differences of 
postmatch patient characteristics. A significant imbalance was 
considered to be present if a >10% standardized difference 
was present between the 2 groups after propensity match.24
Incidence analyses of HHF, death, and composite of HHF 
or death were conducted by treatment group. Only the first 
episode of each outcome was included, and the crude inci-
dence rate (IR) in each group was calculated as the number of 
incident events divided by the total number of person-years 
at risk, and expressed per 100 person-years with 95% con-
fidence interval (CI). Times to first event for the SGLT-2i and 
oGLD groups were compared using Cox proportional hazards 
models and presented as hazard ratios (HRs) and 95% CI for 
each outcome separately within each country.
The primary analysis used an on-treatment approach where 
patients were followed from the start of an index treatment 
and censored at the end of that treatment plus a grace period 
(duration of last issued prescription).
The HRs (95% CI) for each of the end points from each 
individual country were then pooled together for an overall 
weighted summary,25 in which random-effects models with 
inverse variance weighting for each country were imple-
mented.26 Forest plots displaying the country-specific HRs 
(95% CI) along with the pooled overall HR (95% CI) were 
produced.
Multiple sensitivity analyses were conducted: first, the HR 
(95% CI) within each country, and for each outcome, were 
examined after adjusting the crude propensity-matched esti-
mates for multiple covariates that may have confounded the 
relationship between treatment and outcome. The adjusted 
HRs (95% CIs) from each country were pooled and meta-ana-
lyzed using the same method as described above. Second, the 
analyses for each outcome were repeated using intent-to-treat 
analysis, in which patients were followed after discontinua-
tion of index treatment.27–29 Third, the analyses for HHF were 
repeated after stepwise removal of specific oGLD classes from 
the comparator group, to examine whether a specific oGLD 
class contributed disproportionately to the results. Stepwise 
elimination was performed in the following sequence: thia-
zolidinediones, thiazolidinediones+insulin, thiazolidinediones
+insulin+sulfonylureas. Fourth, HHF analyses were repeated 
after excluding patients treated with glucagon-like peptide-1 
receptor agonist at baseline from SGLT-2i and oGLD groups. 
Fifth, primary analyses were repeated separately in the United 
States and Europe. Finally, the association between treat-
ment with SGLT-2i and oGLD was reexamined separately for 
patients that had both in- and outpatient hospital visits for 
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HF, and those that had only inpatient hospital visits for HF in 
Sweden (because these could not be separated in Norway 
and Denmark; and only inpatient HF visits were analyzed in 
other countries).
For power calculations, see the online-only Data 
Supplement Appendix. Because of the deidentified nature of 
patient records, informed consent was not obtained. Analyses 
of deidentified data were conducted in accordance with local 
laws and regulations, and received approvals from respec-
tive Scientific/Ethics/Data Protection Committees. Country-
specific analyses were conducted by independent academic/
statistical groups. The meta-analyses were conducted by 
Statisticon, and validated by the independent academic stat-
isticians at Saint Luke’s Mid America Heart Institute.
RESULTS
Study Population
A total of 1 392 254 new SGLT-2i or oGLD users were 
identified; 166 033 SGLT-2i, and 1 226 221 oGLD overall 
and by country (Figure 1 and online-only Data Supple-
ment Figure I). Before propensity match (online-only 
Data Supplement Table V) patients initiated on SGLT-2i 
were younger, less likely to have chronic kidney disease 
or cardiovascular complications, but more likely to have 
microvascular disease. Greater proportions of patients 
initiated on SGLT-2i versus oGLD received statins and 
antihypertensive drugs, and lower proportions received 
loop diuretics. Patients on SGLT-2i were more likely to 
be treated with other glucose-lowering medication 
classes at baseline. The overlap in propensity scores be-
tween groups before and after the propensity match is 
shown in online-only Data Supplement Figures II and III.
Baseline characteristics were well balanced between 
groups postmatching overall and by country (Table and 
online-only Data Supplement Table VI), with standard-
ized differences for most variables being <10% (online-
only Data Supplement Figure IV). Pre- and postmatch 
standardized differences are shown in online-only Data 
Supplement Table VII. Mean age was 57 years, 44% 
Figure 1. Patient flow chart for all countries/databases 
combined. 
A large number of patients were excluded from the other 
GLD group because of the protocol mandated 1:1 match, 
and given the smaller number of patients in the SGLT-2i 
group. GLD indicates glucose-lowering drug; and SGLT-2i, 
sodium-glucose cotransporter-2 inhibitor.
Table. Baseline Characteristics for All Countries 
Combined
 
SGLT-2 
Inhibitor 
(N=154 528)
Other GLD 
(N=154 528)
Mean age (SD), y 56.9 (10.0) 57.0 (10.6)
Women 68 420 (44.3) 68 772 (44.5)
Established cardiovascular disease* 20 044 (13.0) 20 302 (13.1)
  Acute myocardial infarction 3793 (2.5) 3882 (2.5)
  Unstable angina 2529 (1.6) 2568 (1.7)
  Heart failure 4714 (3.1) 4759 (3.1)
  Atrial fibrillation 5632 (3.6) 5698 (3.7)
  Stroke 6337 (4.1) 6394 (4.1)
  Peripheral arterial disease 5239 (3.4) 5229 (3.4)
Microvascular disease 42 217 (27.3) 42 215 (27.3)
Chronic kidney disease 3920 (2.5) 4171 (2.7)
Frailty (yes)† 11 982 (7.8) 12 731 (8.2)
Baseline glucose-lowering therapies
  Metformin 121 500 (78.6) 123 432 (79.9)
  Sulfonylurea 59 406 (38.4) 59 788 (38.7)
  Dipeptidyl peptidase-4 inhibitor 51 400 (33.3) 50 088 (32.4)
  Thiazolidinedione 13 650 (8.8) 12 970 (8.4)
  Glucagon-like peptide-1 receptor 
agonist
31 355 (20.3) 27 088 (17.5)
  Insulin 45 573 (29.5) 45 097 (29.2)
Cardiovascular therapies
  Antihypertensive therapy‡ 123 696 (80.0) 123 563 (80.0)
   Loop diuretics 14 280 (9.2) 14 314 (9.3)
   Thiazides 42 446 (27.5) 42 510 (27.5)
   Angiotensin-converting enzyme 
inhibitors
66 812 (43.2) 67 067 (43.4)
   Angiotensin receptor blockers 48 718 (31.5) 48 443 (31.4)
  Statin therapy 103 968 (67.3) 104 128 (67.4)
Index year
  2012 21 (0.0) 270 (0.2)
  2013 21 286 (13.8) 25 713 (16.6)
  2014 71 070 (46.0) 58 793 (38.0)
  2015 58 951 (38.1) 66 496 (43.0)
Data are n (%) unless otherwise stated.
*Myocardial infarction, unstable angina, stroke, heart failure, transient 
ischemic attack, coronary revascularization, or occlusive peripheral artery 
disease. 
†In the United Kingdom Clinical Practice Research Datalink/The Health 
Improvement Network, frailty is defined as ≥1 hospitalization within 1 year 
before or on index date, and in other databases it is defined as ≥1 hospital stay 
of ≥3 days within 1 year before the index date.
‡Includes angiotensin-converting enzyme inhibitors, angiotensin receptor 
blockers, Ca2+ channel blockers, β-blockers, and thiazides. 
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were women, and 13% had established CVD. Overall, 
67% of patients received statins, 80% antihypertensive 
medications, 74% with angiotensin-converting enzyme 
inhibitors/angiotensin II receptor blockers, and 79% 
metformin.
The composition of SGLT-2i agents is shown in on-
line-only Data Supplement Table VIII, and the compo-
sition of the index medications in the oGLD group is 
shown in online-only Data Supplement Tables IX and 
X. The composition of SGLT-2i agents in terms of total 
exposure time was balanced between canagliflozin and 
dapagliflozin, with <7% total exposure attributable to 
empagliflozin for all outcomes (Figure 2).
SGLT-2i and HHF
A total of 309 056 patients (154 528 in each group) 
were identified after propensity matching. Cana-
gliflozin, dapagliflozin, and empagliflozin accounted 
for 53%, 42%, and 5% of the total exposure time in 
the SGLT-2i class, respectively (Figure 2A through 2C).
Over 190 164 person-years follow-up, there were 961 
HHF events (IR, 0.51/100 person-years; online-only Data 
Supplement Table XI; IR by treatment group in online-only 
Data Supplement Table XII). Mean duration of follow-up 
for HHF was 239 days in the SGLT-2i group and 211 days in 
the oGLD group (online-only Data Supplement Table XIII). 
Initiation of SGLT-2i versus oGLD was associated with a 
lower risk of HHF (pooled HR, 0.61; 95% CI, 0.51–0.73; 
P<0.001; Figure 3A). HRs favored SGLT-2i in each country 
(P value for heterogeneity 0.17).
SGLT-2i and All-Cause Death
A total of 215 622 patients (107 811 in each group) 
were identified. Canagliflozin, dapagliflozin, and empa-
gliflozin accounted for 42%, 51%, and 7% of SGLT-2i 
exposure time, respectively (Figure 2A through 2C).
Over 153 990 person-years of follow-up, there 
were 1334 events (IR, 0.87/100 person-years; online-
only Data Supplement Table XI; IR by treatment group 
in online-only Data Supplement Table XII). Mean 
duration of follow-up was 271 days in the SGLT-2i 
group and 251 days in the oGLD group (online-only 
Data Supplement Table XIII). Initiation of SGLT-2i ver-
sus oGLD was associated with a lower risk of death 
(pooled HR, 0.49; 95% CI, 0.41–0.57; P<0.001; Fig-
ure 4A). HRs favored SGLT-2i in each country (P value 
for heterogeneity 0.09).
SGLT-2i and Composite Outcome of HHF 
or Death
For the composite outcome, the number of patients was 
identical to the all-cause death analysis. Canagliflozin, 
dapagliflozin, and empagliflozin accounted for 45%, 
49%, and 6% of SGLT-2i exposure time, respectively 
(Figure 2A through 2C).
Over 143 342 person-years of follow-up, there were 
1983 events (IR, 1.38/100 person-years; online-only Data 
Supplement Table XI; IR by treatment group in online-
A
B
C
Figure 2. Contribution of the SGLT-2 inhibitor class as a 
proportion of exposure time in the propensity-match 
cohorts.  
A, All countries combined. B, United States only. C, Euro-
pean countries combined. HHF indicates hospitalization for 
heart failure; and SGLT-2, sodium-glucose cotransporter-2.
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only Data Supplement Table XII). Mean duration of fol-
low-up was 253 days in the SGLT-2i group and from 233 
days in the oGLD group (online-only Data Supplement 
Table XIII). Initiation of SGLT-2i versus oGLD was associ-
ated with a lower risk of HHF or death (pooled HR, 0.54; 
95% CI, 0.48–0.60; P<0.001; Figure 4D). HRs favored 
SGLT-2i in each country (P value for heterogeneity 0.17).
Sensitivity Analyses
For all 3 outcomes, similar results were found after mul-
tivariate adjustment (Figures 3B, 4B, and 4E), using an 
intent-to-treat approach (Figures 3C, 4C, and 4F) and 
stepwise removal of specific oGLD classes (online-only 
Data Supplement Figures V and VI). Comparisons with-
in geographic regions yielded similar results (online-only 
Data Supplement Figure VII). The association between 
treatment with SGLT-2i versus oGLD and lower risk of 
HHF was consistent among patients that had both in- 
and outpatient hospital visits for HF, and those who had 
only inpatient hospital visits for HF in Sweden (online-
only Data Supplement Table XIV).
DISCUSSION
In this large contemporary analysis of real-world clinical 
practice across 6 countries, within a well-matched sam-
ple of >300 000 patients with T2D and nearly 200 000 
patient-years of observation, initiation of SGLT-2i versus 
oGLDs was associated with a 39% lower incidence of 
HHF. Since the overwhelming majority of patients did 
not have established CVD, this suggests that the ben-
efits of SGLT-2i on the prevention of HF may extend to 
lower-risk patients than those enrolled in randomized 
trials so far. These findings were unchanged after ad-
ditional multivariable adjustment, and in multiple sensi-
tivity analyses. Specifically, the results were unchanged 
after sequential removal of several oGLD classes from 
the comparator group, suggesting that the differential 
outcomes observed are unlikely to reflect adverse ef-
fects of comparator drugs, but are rather associated 
with benefit from SGLT-2i. Furthermore, results were 
consistent across countries, regardless of variability in 
healthcare systems and use of specific SGLT-2i (predom-
inantly canagliflozin in the United States; dapagliflozin 
Figure 3. Hazard ratios and 95% CI for the outcome  
of HHF.  
A, On treatment, unadjusted. B, On treatment, adjusted 
(model adjusted for history of heart failure, age, sex, frailty, 
history of myocardial infarction, history of atrial fibrillation, 
hypertension, obesity/body mass index, duration (Continued )
Figure 3 Continued. of diabetes mellitus, ACE inhibitor or 
ARB use, β-blocker or α-blocker use, Ca2+ channel blocker 
use, loop diuretic use, thiazide diuretic use). C, Intent-to-
treat, unadjusted. ACE indicates angiotensin-converting 
enzyme; ARB, angiotensin II receptor blocker; CI, confidence 
interval; CPRD, Clinical Practice Research Datalink; DPV, Dia-
betes Patientenverlaufsdokumentation (Diabetes Prospective 
Follow-Up); HHF, hospitalization for heart failure; oGLD, other 
glucose-lowering drugs; SGLT-2i, sodium-glucose cotransport-
er-2 inhibitor; and THIN, The Health Improvement Network.
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Figure 4. Hazard ratios and 95% CI for the outcome of all-cause death and composite of hospitalization for heart 
failure or all-cause death.  
A, All-cause death: on treatment, unadjusted. B, All-cause death: on treatment, adjusted (model adjusted for history of heart failure, 
age, sex, frailty, history of myocardial infarction, history of atrial fibrillation, hypertension, obesity/body mass index, (Continued )
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in Europe), suggesting an association with the class 
rather than any single agent. Importantly, initiation of 
SGLT-2i versus oGLDs was also associated with a 51% 
lower rate of all-cause death, and a 46% lower rate of 
the combined end point of HHF or all-cause death.
Although intensive glucose lowering has, in random-
ized trials, failed to reduce what are arguably some of 
the most important outcomes in patients with T2D (all-
cause death and incident HF), results from the EMPA-
REG OUTCOME trial demonstrated that such benefits 
are achievable within a short time frame with an SGLT-
2i, likely via nonglycemic mechanisms. Ultimately, the 
main goals of treating patients with T2D are to prolong 
life and improve quality of life. Given that CVD (includ-
ing HF) is a leading cause of mortality/morbidity in T2D, 
the results of the recent cardiovascular outcomes trials 
suggest that the time has come to shift from the nar-
row focus on hemoglobin A1c to a more comprehen-
sive focus in which treatments proven to improve im-
portant outcomes (especially mortality) are prioritized.
Our findings address several key unanswered ques-
tions with regard to the potential role of SGLT-2i in the 
management of T2D, with important clinical implica-
tions. First, our results demonstrate that the effects as-
sociated with the use of SGLT-2i in regard to HHF and 
all-cause death are remarkably similar in real-world 
practice to those seen in the EMPA-REG OUTCOME 
trial. Second, we found no significant heterogeneity in 
results across countries, despite geographic variations 
in the use of specific SGLT-2i, suggesting that the asso-
ciated lower risks for cardiovascular outcomes are likely 
class related. Indeed, for all outcomes evaluated, empa-
gliflozin contributed <7% of total exposure time. Third, 
we evaluated a broader cardiovascular risk population 
in general practice, where the overwhelming majority 
(87%) had no established CVD, suggesting that lower-
risk patients may derive benefits with SGLT-2i similar to 
the patients with higher risk. If confirmed by data from 
ongoing trials (CANVAS30 [Canagliflozin Cardiovascular 
Assessment Study; NCT01032629]; DECLARE [Multi-
center Trial to Evaluate the Effect of Dapagliflozin on 
the Incidence of Cardiovascular Events; NCT01730534]; 
and VERTIS [Cardiovascular Outcomes Following Ertugli-
flozin Treatment in Type 2 Diabetes Mellitus Participants 
With Vascular Disease, The VERTIS CV Study {MK-8835-
004}; NCT01986881]), this would have substantial im-
pact on clinical practice. In this regard, we see the data 
produced from carefully conducted, methodologically 
rigorous, large multicountry epidemiological studies, 
as complementary to those generated by clinical trials, 
as they help establish the real-world effectiveness of 
treatments in a broad population of patients from clini-
cal practice. Indeed, the importance of such studies 
for a broad range of objectives, including evaluation 
of treatment effects and outcomes, and their potential 
for complementing the knowledge gained from clinical 
trials, is being increasingly recognized,31 and the ter-
minology describing these as real-world evidence has 
recently been accepted by major international regula-
tory bodies.32–34
To our knowledge, CVD-REAL is the first large study 
addressing the real-world effectiveness (rather than 
efficacy) of SGLT-2i on specific outcomes of HHF and 
all-cause death across multiple countries. Given that 
SGLT-2i is a novel class, real-world experience is limited. 
Single-country data were previously reported with a 
specific SGLT-2i (dapagliflozin) in Sweden; however, that 
study was limited by the smaller number of patients, 
and focused on different outcomes (hypoglycemia and 
composite of CVD).35 The size of our sample and our 
ability to pool data from diverse sources allowed us to 
collect a large number of events, and examine the sta-
bility of results across various cardiovascular outcomes, 
multiple countries (with variable use of specific SGLT-2i), 
and perform numerous sensitivity analyses.
Our findings should be examined within the context 
of several potential limitations. First, given the observa-
tional nature of the study, and despite robust propen-
sity-matching and multiple sensitivity analyses, a pos-
sibility of residual, unmeasured confounding, cannot 
be excluded. Second, we focused on HHF and all-cause 
death, and did not examine other events, such as myo-
cardial infarction and stroke. However, HF is arguably 
the most lethal T2D complication9,36 and is associated 
with particularly poor survival.11 Third, we did not ex-
amine safety. Fourth, despite a large number of patient-
years of follow up, SGLT-2i experience in real-world 
practice is still relatively limited; longer-term follow-up 
will be required to examine if effects are sustained over 
time. Fifth, there were differences in the definitions of 
Figure 4 Continued. duration of diabetes mellitus, ACE inhibitor or ARB use, β-blocker or α-blocker use, Ca2+ channel 
blocker use, loop diuretic use, thiazide diuretic use). C, All-cause death: intent-to-treat, unadjusted. D, Hospitalization for 
heart failure or all-cause death: on treatment, unadjusted. E, Hospitalization for heart failure or all-cause death: on treat-
ment, adjusted (model adjusted for history of heart failure, age, sex, frailty, history of myocardial infarction, history of atrial 
fibrillation, hypertension, obesity/body mass index, duration of diabetes mellitus, ACE inhibitor or ARB use, β-blocker or 
α-blocker use, Ca2+ channel blocker use, loop diuretic use, thiazide diuretic use). F, Hospitalization for heart failure or all-
cause death: intent-to-treat, unadjusted. ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; 
CI, confidence interval; CPRD, Clinical Practice Research Datalink; DPV, Diabetes Patientenverlaufsdokumentation (Diabetes 
Prospective Follow-Up); oGLD, other glucose-lowering drugs; SGLT-2i, sodium-glucose cotransporter-2 inhibitor; and THIN, 
The Health Improvement Network.
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HHF across countries; however, the results were con-
sistent across countries and in sensitivity analyses spe-
cifically performed to examine these differences. Finally, 
our study did not address the mechanisms linking the 
use of SGLT-2i and associated cardiovascular benefits. 
However, this knowledge gap is being examined by 
mechanistic investigations across the class.37–39
CONCLUSION
In this large multinational study, treatment with SGLT-2i 
versus oGLDs was associated with lower rates of HHF 
and death, suggesting that the benefits previously re-
ported with empagliflozin in the context of a random-
ized trial may be applicable to a broad population of 
patients with T2D in real-world practice. The lack of 
heterogeneity in results across countries, despite geo-
graphic variations in the use of specific SGLT-2i, sug-
gests a class effect for SGLT-2i.
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Characteristics of the databases 
Truven Health MarketScan® Commercial Claims and Encounters (Commercial) and Medicare Supplemental and 
Coordination of Benefits (Medicare Supplemental) databases comprise enrolment information, demographic 
information and inpatient medical, outpatient medical and outpatient pharmacy claims data from over 300 large 
self-insured US employers and over 25 US health plans1. These study databases satisfy the conditions set forth 
in Sections 164.514 (a)-(b)1ii of the Health Insurance Portability and Accountability Act of 1996 privacy rule 
regarding the determination and documentation of statistically de-identified data Thus, the study did not require 
external IRB or ethics review. The Truven MarketScan database has been used for comparative effectiveness 
research since 1989, with over 1100 peer-reviewed publications overall and is considered to be nationally 
representative in the US for the included patient populations.2  Truven MarketScan is highly representative of the 
US commercially insured population aged <65 years, without contributing any specific bias to create differences 
from the commercially insured population as a whole. Comparisons of age, gender, and region for Truven 
MarketScan with US Census data (2010) demonstrate close similarities between the two datasets (data on file).  
Clinical Practice Research Datalink (CPRD) holds anonymized longitudinal primary care patient records collected 
from over 670 general practices across the UK, covering >11.3 million patients. It includes diagnoses, issued 
drug prescriptions, clinical measures taken within the general practice, lab tests and referrals to specialist care.3 
Hospitalisation information and specialist care notes are generally recorded by the general practitioner into the 
primary care patient records. Of the UK practices included in CPRD, 58% are linked to the Hospital Episode 
Statistics (HES) dataset3 with detailed hospitalisation information (excluding drug use) on all hospitalisation 
episodes in England, and to death certificates from the Office of National Statistics (ONS) to derive estimates of 
all-cause and cause-specific death. CPRD includes approximately 6.9% of the UK population, and patients are 
broadly representative of the UK general population.3 Herrett et al 3 assesses the representativeness of CPRD by 
comparing the age and sex distribution within CPRD to the UK Census in 2011. They found that CPRD was 
broadly representative of the UK population with respect to age and sex. In addition, Herrett et al 2010 4 
published a literature review assessing the validation and validity of diagnoses in CPRD (formerly known as 
GPRD). They concluded that overall, estimates of validity were high. A detailed description of CPRD can be 
found in a paper by Williams et al.5 This generalizability of CPRD to the UK population has resulted in CPRD 
being used in over 1000 publications.3  
The Health Improvement Network (THIN) includes data from >580 UK practices, with similar data to CPRD.6 
THIN coverage of the UK population by 2013 was 5.67%7 and  the representativeness of THIN was described by 
Blak et al by comparing the distribution of deprivation, morbidities (Quality and Outcomes Framework [QOF] 
conditions) and demographics to national statistics and national QOF 2006/2007 data.8 They demonstrated that 
THIN is representative of the UK population with respect to morbidities, demographics, and mortality rates. 
Furthermore, in THIN, it was found that between 1990 and 2009 the standardized mortality ratio ranged from 
0.81 (95% CI: 0.39–1.49; 1990) to 0.93 (95% CI: 0.48–1.64; 1995). Adjusting for demographics/deprivation, the 
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2006 THIN death rate was 9.08/1000 population, which is consistent with the national death rate of 9.4/1000 
population. When Blak et al. was originally published, THIN included 532 general practices. Currently there are 
approximately 600 general practices. A description of the development of THIN is described in Bourke et al.9 
Lewis et al validated THIN by comparing drug-disease associations found in the original GPRD practices 
included in THIN, to drug-disease associations found in the new practices included in THIN.10 They concluded 
that: ‘THIN data that are collected outside of the GPRD appear as valid as the data collected as part of the 
GPRD’. Other validation studies of THIN are also available,11, 12 and similar to CPRD, THIN has been used for 
numerous publications (~400 to date; http://www.epic-uk.org/our-data/statistics.shtml.), some of which compare 
THIN data results to external measures, demonstrating similarities.13-18 
Some of the general practices providing data to CPRD are also providing data to THIN. Therefore, there is an 
overlap and a potential to combine the two databases in order to increase patient numbers. A recent study within 
diabetes has shown that 61% of CPRD patients are also included in THIN.6 This overlap in patients has been 
taken into account in the present study so that no individual is double counted. The duplicated practices list 
between CPRD and THIN was obtained by looking for coincidences of patients by practices between both 
databases. The parameters used for the match were sex, year of birth, family id, and date and Read code of 
diabetes.7, 19 For the analyses all THIN practices were retained and the non-overlapping CPRD HES and ONS 
linked practices. In CPRD, HHF was identified in linked HES with International Statistical Classification of 
Diseases and Related Health Problems (ICD-system) 10 codes I50.x and all-cause death was identified in linked 
ONS death data. HHF and all-cause death was identified in the general practice medical records in THIN. For 
HFF, free text from THIN was collected within +-365 days of event and reviewed to ascertain and validate the 
cause of hospitalisation and the event date. The reviewers were blinded to the index medication. Patients were 
selected from THIN and/or CPRD from November 2012 to September 2015 (THIN) and to January 2016 (CPRD). 
This study was approved by the Scientific Review Committee (SRC) of THIN; protocol approval number: 
16THIN027A1. Further, the Independent Scientific Advisory Committee (ISAC) of CPRD approved it; protocol 
approval number: 16_064RAR.    
The Diabetes-Patienten-Verlaufsdokumentation (DPV; or “Diabetes Prospective Follow-up”) initiative involves 
more than 400 clinical centres predominantly from Germany and Austria, documenting data pertaining to 
diabetes. Similar to an electronic medical record, relevant data are documented only once and are available for 
numerous purposes: graphical and tabular description, medical report, treatment plan, diabetes passport, 
reminder on upcoming visits (watchdog), certification of centers and type 2 diabetes program (DMP) 
documentation. Every 6 months, anonymized data are sent to the University of Ulm, Germany.20 Analyses are 
conducted separately for pediatric and adult patients either anonymised or centre-based after prior written 
informed consent for regional quality circles. Data of the anonymised DPV registry are used for treatment 
research in order to investigate practice-oriented questions. A publication list can be found on the website under 
‘publications’ (www.d-p-v.eu). Data from this registry have been used extensively in multi-center outcomes 
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research, with 452 centers participating. The DPV-initiative is the multicenter benchmark database for patients 
with diabetes in Germany, includes all levels of diabetes care for the German population of patients with T2D, 
and has been used in over 370 peer-reviewed publications.20 The DPV Type 2 diabetes population is consistent 
with that observed in the national German Health Interview and Examination Surveys 21 when considering the 
inclusion and exclusion criteria of the CVD-REAL study. In addition, demographic characteristics of the DPV 
population are consistent with other large data collections of patients with diabetes from Germany, such as the 
DMP data from Northrhine (https://www.kvno.de/downloads/quali/qualbe_dmp14.pdf) or the DIVE registry 
(http://www.dive-register.de/). 
The National Prescribed Drug Registers in Sweden, Norway and Denmark have full coverage of each country’s 
population. Patients were followed with regard to outcome in the National Patient Register and National Cause of 
Death Register. The Swedish national  database22 includes information from linkage of three national Swedish 
registries held by the Swedish National Board of Health and Welfare, with full coverage of the Swedish 
population: 1) The Prescribed Drug Register July 1, 2005 to December 2016, covering all drug prescriptions filled 
using Anatomical Therapeutic Chemical codes; 2) The Cause of Death Register 1961–2015; 3) The National 
Patient Register covering all hospital admissions and discharge diagnoses in 1987–2015, discharge diagnoses, 
specialized care and open patient clinic visits in 2001–2015. Diagnoses are recorded according to the 
International Statistical Classification of Diseases and Related Health Problems (ICD) system. Similarly, the 
Norwegian national database23 includes type 2 diabetes patient information from three national Norwegian 
registries with full coverage of the Norwegian population: the Norwegian Prescription Database (July 2004 to July 
2016) covering all filled drug prescriptions using ATC codes; the Norwegian Cause of Death Register (1958 to 
2014); and the Norwegian Patient Register covering all hospital out-patient clinic visit and discharge diagnoses 
and all hospital discharge diagnoses for the years 2008 to July 2016. Diagnoses are recorded according to the 
ICD-system. Data linkage is performed by the Norwegian Institute of Public Health. The Danish national 
database24 also has a similar structure, and includes T2D patient information from three national Danish 
registries with full coverage of the Danish population: the Prescribed Drug Register (1990 to 2015) covering all 
filled drug prescriptions using ATC codes; the Cause of Death Register (1952– to 2014); and the National Patient 
Register covering all open patient clinic visit diagnoses for 2000 to 2015 and all hospital discharge diagnoses for 
the years 1980 to 2015, and discharge diagnoses and. Diagnoses are recorded according to the ICD-system. All 
three registers are held by the Statistics Denmark. Data from Statistics Denmark were made available following 
an application to Statistics Denmark. The Danish study was approved by the Danish Data Protection Agency 
(Datatilsynet, registration number 2015-41-4148).  
Data were anonymised, and the requirement for informed consent was therefore waived according to standard 
analytical procedures with each database owner.  
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Statistical power calculations 
For the primary outcome (HHF) a risk reduction of 20% for SGLT-2i versus oGLD was considered clinically 
meaningful. For 85% power to detect a risk reduction of 20% with a two-sided α-level of 0.05 and a 1:1 treatment 
allocation (SGLT-2i vs. oGLD), a total of 730 events across the matched treatment groups in all the datasets was 
required. As there were a total of 961 HHF events within the matched cohorts, we had sufficient power to perform 
the HHF analysis.   
Analyses were conducted using R- version 3.2.325, 26 in Sweden, Norway and Denmark, STATA version 12.0 
(StataCorp LP, College Station, TX, US) in the UK, STATA version 12.0 (StataCorp LP, College Station, TX, US) 
and SAS version 9.4 (Cary, NC) in the US, and SAS version 9.4 (TS1M1) (Cary, NC, US) in Germany.  
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SUPPLEMENTARY TABLES 
 
Table S1. ICD and Read codes for Type 2 diabetes, Type 1 diabetes and gestational diabetes 
Type 2 diabetes 
ICD codes 
ICD-9 250.X0, 250.X2  
ICD-10 codes E11 and 024.1 
Read codes 
66A4.00 Diabetic on oral treatment 
66Ao.00 Diabetes type 2 review 
66At100 Type II diabetic dietary review 
66At111 Type 2 diabetic dietary review 
66AV.00 Diabetic on insulin and oral treatment 
C100100 Diabetes mellitus, adult onset, no mention of complication 
C100111 Maturity onset diabetes 
C100112 Non-insulin dependent diabetes mellitus 
C101100 Diabetes mellitus, adult onset, with ketoacidosis 
C102100 Diabetes mellitus, adult onset, with hyperosmolar coma 
C103100 Diabetes mellitus, adult onset, with ketoacidotic coma 
C104100 Diabetes mellitus, adult onset, with renal manifestation 
C105100 Diabetes mellitus, adult onset, + ophthalmic manifestation 
C106100 Diabetes mellitus, adult onset, + neurological manifestation 
C107100 Diabetes mellitus, adult, + peripheral circulatory disorder 
C107200 Diabetes mellitus, adult with gangrene 
C107400 NIDDM with peripheral circulatory disorder 
C109.00 Non-insulin dependent diabetes mellitus 
C109.11 NIDDM - Non-insulin dependent diabetes mellitus 
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C109.12 Type 2 diabetes mellitus 
C109.13 Type II diabetes mellitus 
C109000 Non-insulin-dependent diabetes mellitus with renal comps 
C109011 Type II diabetes mellitus with renal complications 
C109012 Type 2 diabetes mellitus with renal complications 
C109100 Non-insulin-dependent diabetes mellitus with ophthalm comps 
C109111 Type II diabetes mellitus with ophthalmic complications 
C109112 Type 2 diabetes mellitus with ophthalmic complications 
C109200 Non-insulin-dependent diabetes mellitus with neuro comps 
C109211 Type II diabetes mellitus with neurological complications 
C109212 Type 2 diabetes mellitus with neurological complications 
C109300 Non-insulin-dependent diabetes mellitus with multiple comps 
C109400 Non-insulin dependent diabetes mellitus with ulcer 
C109411 Type II diabetes mellitus with ulcer 
C109412 Type 2 diabetes mellitus with ulcer 
C109500 Non-insulin dependent diabetes mellitus with gangrene 
C109511 Type II diabetes mellitus with gangrene 
C109512 Type 2 diabetes mellitus with gangrene 
C109600 Non-insulin-dependent diabetes mellitus with retinopathy 
C109611 Type II diabetes mellitus with retinopathy 
C109612 Type 2 diabetes mellitus with retinopathy 
C109700 Non-insulin dependent diabetes mellitus - poor control 
C109711 Type II diabetes mellitus - poor control 
C109712 Type 2 diabetes mellitus - poor control 
C109900 Non-insulin-dependent diabetes mellitus without complication 
C109A00 Non-insulin dependent diabetes mellitus with mononeuropathy 
C109A11 Type II diabetes mellitus with mononeuropathy 
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C109B00 Non-insulin dependent diabetes mellitus with polyneuropathy 
C109B11 Type II diabetes mellitus with polyneuropathy 
C109C00 Non-insulin dependent diabetes mellitus with nephropathy 
C109C11 Type II diabetes mellitus with nephropathy 
C109C12 Type 2 diabetes mellitus with nephropathy 
C109D00 Non-insulin dependent diabetes mellitus with hypoglyca coma 
C109D11 Type II diabetes mellitus with hypoglycaemic coma 
C109D12 Type 2 diabetes mellitus with hypoglycaemic coma 
C109E00 Non-insulin depend diabetes mellitus with diabetic cataract 
C109E11 Type II diabetes mellitus with diabetic cataract 
C109E12 Type 2 diabetes mellitus with diabetic cataract 
C109F00 Non-insulin-dependent d m with peripheral angiopath 
C109F11 Type II diabetes mellitus with peripheral angiopathy 
C109F12 Type 2 diabetes mellitus with peripheral angiopathy 
C109G00 Non-insulin dependent diabetes mellitus with arthropathy 
C109G11 Type II diabetes mellitus with arthropathy 
C109G12 Type 2 diabetes mellitus with arthropathy 
C109H00 Non-insulin dependent d m with neuropathic arthropathy 
C109H11 Type II diabetes mellitus with neuropathic arthropathy 
C109H12 Type 2 diabetes mellitus with neuropathic arthropathy 
C109J00 Insulin treated Type 2 diabetes mellitus 
C109J11 Insulin treated non-insulin dependent diabetes mellitus 
C109J12 Insulin treated Type II diabetes mellitus 
C109K00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
C10C.11 Maturity onset diabetes in youth 
C10D.00 Diabetes mellitus autosomal dominant type 2 
C10D.11 Maturity onset diabetes in youth type 2 
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C10F.00 Type 2 diabetes mellitus 
C10F.11 Type II diabetes mellitus 
C10F000 Type 2 diabetes mellitus with renal complications 
C10F011 Type II diabetes mellitus with renal complications 
C10F100 Type 2 diabetes mellitus with ophthalmic complications 
C10F111 Type II diabetes mellitus with ophthalmic complications 
C10F200 Type 2 diabetes mellitus with neurological complications 
C10F211 Type II diabetes mellitus with neurological complications 
C10F300 Type 2 diabetes mellitus with multiple complications 
C10F311 Type II diabetes mellitus with multiple complications 
C10F400 Type 2 diabetes mellitus with ulcer 
C10F411 Type II diabetes mellitus with ulcer 
C10F500 Type 2 diabetes mellitus with gangrene 
C10F511 Type II diabetes mellitus with gangrene 
C10F600 Type 2 diabetes mellitus with retinopathy 
C10F611 Type II diabetes mellitus with retinopathy 
C10F700 Type 2 diabetes mellitus - poor control 
C10F711 Type II diabetes mellitus - poor control 
C10F900 Type 2 diabetes mellitus without complication 
C10F911 Type II diabetes mellitus without complication 
C10FA00 Type 2 diabetes mellitus with mononeuropathy 
C10FA11 Type II diabetes mellitus with mononeuropathy 
C10FB00 Type 2 diabetes mellitus with polyneuropathy 
C10FB11 Type II diabetes mellitus with polyneuropathy 
C10FC00 Type 2 diabetes mellitus with nephropathy 
C10FC11 Type II diabetes mellitus with nephropathy 
C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma 
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C10FD11 Type II diabetes mellitus with hypoglycaemic coma 
C10FE00 Type 2 diabetes mellitus with diabetic cataract 
C10FE11 Type II diabetes mellitus with diabetic cataract 
C10FF00 Type 2 diabetes mellitus with peripheral angiopathy 
C10FF11 Type II diabetes mellitus with peripheral angiopathy 
C10FG00 Type 2 diabetes mellitus with arthropathy 
C10FG11 Type II diabetes mellitus with arthropathy 
C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy 
C10FJ00 Insulin treated Type 2 diabetes mellitus 
C10FJ11 Insulin treated Type II diabetes mellitus 
C10FK00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
C10FL00 Type 2 diabetes mellitus with persistent proteinuria 
C10FL11 Type II diabetes mellitus with persistent proteinuria 
C10FM00 Type 2 diabetes mellitus with persistent microalbuminuria 
C10FM11 Type II diabetes mellitus with persistent microalbuminuria 
C10FN00 Type 2 diabetes mellitus with ketoacidosis 
C10FP00 Type 2 diabetes mellitus with ketoacidotic coma 
C10FQ00 Type 2 diabetes mellitus with exudative maculopathy 
C10FR00 Type 2 diabetes mellitus with gastroparesis 
C10K.00 Type A insulin resistance 
C10K000 Type A insulin resistance without complication 
C10z100 Diabetes mellitus, adult onset, + unspecified complication 
L180600 Pre-existing diabetes mellitus, non-insulin-dependent 
Type 1 diabetes 
ICD codes 
ICD-9 codes 250.x1, 250.X3 
ICD-10 codes E10 and O24 
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Read codes 
66An.00 Diabetes type 1 review 
C108D11 Type I diabetes mellitus with nephropathy 
66An.00 Diabetes type 1 review 
66At000 Type I diabetic dietary review 
66At011 Type 1 diabetic dietary review 
C100011 Insulin dependent diabetes mellitus 
C101000 Diabetes mellitus, juvenile type, with ketoacidosis 
C102000 Diabetes mellitus, juvenile type, with hyperosmolar coma 
C103000 Diabetes mellitus, juvenile type, with ketoacidotic coma 
C104000 Diabetes mellitus, juvenile type, with renal manifestation 
C105000 Diabetes mellitus, juvenile type, + ophthalmic manifestation 
C106000 Diabetes mellitus, juvenile, + neurological manifestation 
C107000 Diabetes mellitus, juvenile +peripheral circulatory disorder 
C107300 IDDM with peripheral circulatory disorder 
C108.00 Insulin dependent diabetes mellitus 
C108.11 IDDM-Insulin dependent diabetes mellitus 
C108.12 Type 1 diabetes mellitus 
C108.13 Type I diabetes mellitus 
C108000 Insulin-dependent diabetes mellitus with renal complications 
C108011 Type I diabetes mellitus with renal complications 
C108012 Type 1 diabetes mellitus with renal complications 
C108100 Insulin-dependent diabetes mellitus with ophthalmic comps 
C108112 Type 1 diabetes mellitus with ophthalmic complications 
C108200 Insulin-dependent diabetes mellitus with neurological comps 
C108211 Type I diabetes mellitus with neurological complications 
C108212 Type 1 diabetes mellitus with neurological complications 
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C108300 Insulin dependent diabetes mellitus with multiple complicatn 
C108400 Unstable insulin dependent diabetes mellitus 
C108411 Unstable type I diabetes mellitus 
C108412 Unstable type 1 diabetes mellitus 
C108500 Insulin dependent diabetes mellitus with ulcer 
C108511 Type I diabetes mellitus with ulcer 
C108512 Type 1 diabetes mellitus with ulcer 
C108600 Insulin dependent diabetes mellitus with gangrene 
C108700 Insulin dependent diabetes mellitus with retinopathy 
C108711 Type I diabetes mellitus with retinopathy 
C108712 Type 1 diabetes mellitus with retinopathy 
C108800 Insulin dependent diabetes mellitus - poor control 
C108811 Type I diabetes mellitus - poor control 
C108812 Type 1 diabetes mellitus - poor control 
C108900 Insulin dependent diabetes maturity onset 
C108911 Type I diabetes mellitus maturity onset 
C108912 Type 1 diabetes mellitus maturity onset 
C108A00 Insulin-dependent diabetes without complication 
C108A11 Type I diabetes mellitus without complication 
C108B00 Insulin dependent diabetes mellitus with mononeuropathy 
C108B11 Type I diabetes mellitus with mononeuropathy 
C108C00 Insulin dependent diabetes mellitus with polyneuropathy 
C108D00 Insulin dependent diabetes mellitus with nephropathy 
C108D11 Type I diabetes mellitus with nephropathy 
C108E00 Insulin dependent diabetes mellitus with hypoglycaemic coma 
C108E11 Type I diabetes mellitus with hypoglycaemic coma 
C108E12 Type 1 diabetes mellitus with hypoglycaemic coma 
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C108F00 Insulin dependent diabetes mellitus with diabetic cataract 
C108F11 Type I diabetes mellitus with diabetic cataract 
C108G00 Insulin dependent diab mell with peripheral angiopathy 
C108H00 Insulin dependent diabetes mellitus with arthropathy 
C108H11 Type I diabetes mellitus with arthropathy 
C108J00 Insulin dependent diab mell with neuropathic arthropathy 
C108J11 Type I diabetes mellitus with neuropathic arthropathy 
C108J12 Type 1 diabetes mellitus with neuropathic arthropathy 
C10C.12 Maturity onset diabetes in youth type 1 
C10E.00 Type 1 diabetes mellitus 
C10E.11 Type I diabetes mellitus 
C10E.12 Insulin dependent diabetes mellitus 
C10E000 Type 1 diabetes mellitus with renal complications 
C10E012 Insulin-dependent diabetes mellitus with renal complications 
C10E100 Type 1 diabetes mellitus with ophthalmic complications 
C10E111 Type I diabetes mellitus with ophthalmic complications 
C10E112 Insulin-dependent diabetes mellitus with ophthalmic comps 
C10E200 Type 1 diabetes mellitus with neurological complications 
C10E212 Insulin-dependent diabetes mellitus with neurological comps 
C10E300 Type 1 diabetes mellitus with multiple complications 
C10E311 Type I diabetes mellitus with multiple complications 
C10E312 Insulin dependent diabetes mellitus with multiple complicat 
C10E400 Unstable type 1 diabetes mellitus 
C10E411 Unstable type I diabetes mellitus 
C10E412 Unstable insulin dependent diabetes mellitus 
C10E500 Type 1 diabetes mellitus with ulcer 
C10E511 Type I diabetes mellitus with ulcer 
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C10E512 Insulin dependent diabetes mellitus with ulcer 
C10E600 Type 1 diabetes mellitus with gangrene 
C10E611 Type I diabetes mellitus with gangrene 
C10E700 Type 1 diabetes mellitus with retinopathy 
C10E711 Type I diabetes mellitus with retinopathy 
C10E712 Insulin dependent diabetes mellitus with retinopathy 
C10E800 Type 1 diabetes mellitus - poor control 
C10E812 Insulin dependent diabetes mellitus - poor control 
C10E900 Type 1 diabetes mellitus maturity onset 
C10E911 Type I diabetes mellitus maturity onset 
C10E912 Insulin dependent diabetes maturity onset 
C10EA00 Type 1 diabetes mellitus without complication 
C10EA11 Type I diabetes mellitus without complication 
C10EA12 Insulin-dependent diabetes without complication 
C10EB00 Type 1 diabetes mellitus with mononeuropathy 
C10EC00 Type 1 diabetes mellitus with polyneuropathy 
C10EC11 Type I diabetes mellitus with polyneuropathy 
C10EC12 Insulin dependent diabetes mellitus with polyneuropathy 
C10ED00 Type 1 diabetes mellitus with nephropathy 
C10ED12 Insulin dependent diabetes mellitus with nephropathy 
C10EE00 Type 1 diabetes mellitus with hypoglycaemic coma 
C10EE12 Insulin dependent diabetes mellitus with hypoglycaemic coma 
C10EF00 Type 1 diabetes mellitus with diabetic cataract 
C10EF12 Insulin dependent diabetes mellitus with diabetic cataract 
C10EG00 Type 1 diabetes mellitus with peripheral angiopathy 
C10EH00 Type 1 diabetes mellitus with arthropathy 
C10EJ00 Type 1 diabetes mellitus with neuropathic arthropathy 
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C10EK00 Type 1 diabetes mellitus with persistent proteinuria 
C10EL00 Type 1 diabetes mellitus with persistent microalbuminuria 
C10EL11 Type I diabetes mellitus with persistent microalbuminuria 
C10EM00 Type 1 diabetes mellitus with ketoacidosis 
C10EM11 Type I diabetes mellitus with ketoacidosis 
C10EN00 Type 1 diabetes mellitus with ketoacidotic coma 
C10EN11 Type I diabetes mellitus with ketoacidotic coma 
C10EP00 Type 1 diabetes mellitus with exudative maculopathy 
C10EP11 Type I diabetes mellitus with exudative maculopathy 
C10EQ00 Type 1 diabetes mellitus with gastroparesis 
C10z000 Diabetes mellitus, juvenile type, + unspecified complication 
L180500 Pre-existing diabetes mellitus, insulin-dependent 
8Hj3.00 Referral to DAFNE diabetes structured education programme 
8Hj4.00 Referral to DESMOND diabetes structured education programme 
8Hj5.00 Referral to XPERT diabetes structured education programme 
8I82.00 Did not complete DAFNE diabetes structured education program 
8I83.00 Did not complete DESMOND diabetes structured educat program 
8I84.00 Did not complete XPERT diabetes structured education program 
9NiC.00 Did not attend DAFNE diabetes structured education programme 
9NiD.00 Did not attend DESMOND diabetes structured education program 
9NiE.00 Did not attend XPERT diabetes structured education programme 
9OLG.00 Attended XPERT diabetes structured education programme 
9OLH.00 Attended DAFNE diabetes structured education programme 
9OLJ.00 DAFNE diabetes structured education programme completed 
9OLK.00 DESMOND diabetes structured education programme completed 
9OLL.00 XPERT diabetes structured education programme completed 
Gestational Diabetes 
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ICD codes 
ICD-9 codes 648.8  
ICD-10:O24.4 
Read codes 
ZC2CB00 Dietary advice for gestational diabetes 
ZV13F00 [V]Personal history of gestational diabetes mellitus 
L180900 Gestational diabetes mellitus 
L180811 Gestational diabetes mellitus 
8CE0000 Gestational diabetes information leaflet given 
66Ay.00 Gestational diabetes mellitus annual review 
8CE0000 Gestational diabetes information leaflet given 
Q44B.00 Syndrome of infant of mother with gestational diabetes 
66AX.00 Diabetes: shared care in pregnancy - diabetol and obstet 
6761.00 Diabetic pre-pregnancy counselling 
L180.00 Diabetes mellitus during pregnancy/childbirth/puerperium 
L180000 Diabetes mellitus - unspec whether in pregnancy/puerperium 
L180100 Diabetes mellitus during pregnancy - baby delivered 
L180300 Diabetes mellitus during pregnancy - baby not yet delivered 
L180800 Diabetes mellitus arising in pregnancy 
L180z00 Diabetes mellitus in pregnancy/childbirth/puerperium NOS 
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Table S2. Read codes for history of cardiovascular events  
Myocardial infarction 
G30..00 Acute myocardial infarction  
G30..13 Cardiac rupture following myocardial infarction (MI)  
G300.00 Acute anterolateral infarction  
G301.00 Other specified anterior myocardial infarction  
G301000 Acute anteroapical infarction  
G30..11 Attack - heart  
G30..14 Heart attack  
G30..15 MI - acute myocardial infarction  
G301100 Acute anteroseptal infarction  
G301z00 Anterior myocardial infarction NOS  
G302.00 Acute inferolateral infarction  
G303.00 Acute inferoposterior infarction  
G304.00 Posterior myocardial infarction NOS  
G305.00 Lateral myocardial infarction NOS  
G306.00 True posterior myocardial infarction  
G307.00 Acute subendocardial infarction  
G307000 Acute non-Q wave infarction  
G308.00 Inferior myocardial infarction NOS  
G309.00 Acute Q-wave infarct  
G30B.00 Acute posterolateral myocardial infarction  
G30X.00 Acute transmural myocardial infarction of unspecif site  
G30X000 Acute ST segment elevation myocardial infarction  
G30y.00 Other acute myocardial infarction  
G30y000 Acute atrial infarction  
G30y100 Acute papillary muscle infarction  
G30y200 Acute septal infarction  
G30yz00 Other acute myocardial infarction NOS  
G30z.00 Acute myocardial infarction NOS  
G31..00 Other acute and subacute ischaemic heart disease  
G311500 Acute coronary syndrome  
G310.00 Postmyocardial infarction syndrome  
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G31y100 Microinfarction of heart  
G31y200 Subendocardial ischaemia  
G35..00 Subsequent myocardial infarction  
G350.00 Subsequent myocardial infarction of anterior wall  
G351.00 Subsequent myocardial infarction of inferior wall  
G353.00 Subsequent myocardial infarction of other sites  
G35X.00 Subsequent myocardial infarction of unspecified site  
3232.00 ECG: old myocardial infarction  
3235.00 ECG: subendocardial infarct  
323Z.00 ECG: myocardial infarct NOS  
889A.00 Diab mellit insulin-glucose infus acute myocardial infarct  
G307100 Acute non-ST segment elevation myocardial infarction  
G312.00 Coronary thrombosis not resulting in myocardial infarction  
G36..00 Certain current complication follow acute myocardial infarct  
G360.00 Haemopericardium/current comp folow acut myocard infarct  
G364.00 Ruptur chordae tendinae/curr comp fol acute myocard infarct  
G365.00 Rupture papillary muscle/curr comp fol acute myocard infarct  
G384.00 Postoperative subendocardial myocardial infarction  
Gyu3100 [X]Other current complicatns following acute myocard infarct  
Gyu3400 [X]Acute transmural myocardial infarction of unspecif site  
Unstable Angina 
G311.11 Crescendo angina  
G311.13 Unstable angina  
G311.14 Angina at rest  
G311100 Unstable angina  
G311200 Angina at rest  
G311300 Refractory angina  
G311400 Worsening angina  
G330.00 Angina decubitus  
G330000 Nocturnal angina  
G330z00 Angina decubitus NOS  
G331.00 Prinzmetal's angina  
G331.11 Variant angina pectoris  
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Ischemic Stroke 
14A7.00 H/O: CVA/stroke  
14A7.11 H/O: CVA  
14A7.12 H/O: stroke  
14AK.00 H/O: Stroke in last year  
662M100 Stroke 6 month review  
662M200 Stroke initial post discharge review  
8HBJ.00 Stroke / transient ischaemic attack referral  
G63..11 Infarction - precerebral  
G63y000 Cerebral infarct due to thrombosis of precerebral arteries  
G63y100 Cerebral infarction due to embolism of precerebral arteries  
G64..11 CVA - cerebral artery occlusion  
G64..12 Infarction - cerebral  
G64..13 Stroke due to cerebral arterial occlusion  
G640.00 Cerebral thrombosis  
G640000 Cerebral infarction due to thrombosis of cerebral arteries  
G641.00 Cerebral embolism  
G641.11 Cerebral embolus  
G641000 Cerebral infarction due to embolism of cerebral arteries  
G64z.00 Cerebral infarction NOS  
G64z.11 Brainstem infarction NOS  
G64z.12 Cerebellar infarction  
G64z000 Brainstem infarction  
G64z100 Wallenberg syndrome  
G64z111 Lateral medullary syndrome  
G64z200 Left sided cerebral infarction  
G64z300 Right sided cerebral infarction  
G64z400 Infarction of basal ganglia  
G654.00 Multiple and bilateral precerebral artery syndromes  
G66..00 Stroke and cerebrovascular accident unspecified  
G66..11 CVA unspecified  
G66..12 Stroke unspecified  
G66..13 CVA - Cerebrovascular accident unspecified  
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G660.00 Middle cerebral artery syndrome  
G661.00 Anterior cerebral artery syndrome  
G662.00 Posterior cerebral artery syndrome  
G663.00 Brain stem stroke syndrome  
G664.00 Cerebellar stroke syndrome  
G665.00 Pure motor lacunar syndrome  
G666.00 Pure sensory lacunar syndrome  
G667.00 Left sided CVA  
G668.00 Right sided CVA  
G675.00 Moyamoya disease  
G676.00 Nonpyogenic venous sinus thrombosis  
G676000 Cereb infarct due cerebral venous thrombosis, nonpyogenic  
G678.00 Cereb autosom dominant arteriop subcort infarcts leukoenceph  
G683.00 Sequelae of cerebral infarction  
G68X.00 Sequelae of stroke,not specfd as h'morrhage or infarction  
G6W..00 Cereb infarct due unsp occlus/stenos precerebr arteries  
G6X..00 Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs  
Gyu6300 [X]Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs  
Gyu6400 [X]Other cerebral infarction  
Gyu6C00 [X]Sequelae of stroke,not specfd as h'morrhage or infarction  
Gyu6G00 [X]Cereb infarct due unsp occlus/stenos precerebr arteries  
L440.12 Stroke in the puerperium  
ZLEP.00 Discharge from stroke serv  
ZV12511 [V]Personal history of stroke  
ZV12512 [V]Personal history of cerebrovascular accident (CVA)  
Hemostroke 
7004100 Evacuation of haematoma from temporal lobe of brain 
7004200 Evacuation of haematoma from cerebellum 
7004300 Evacuation of intracerebral haematoma NEC 
7008200 Aspiration of haematoma of brain tissue 
G61..00 Intracerebral haemorrhage 
G61..11 CVA - cerebrovascular accid due to intracerebral haemorrhage 
G61..12 Stroke due to intracerebral haemorrhage 
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G610.00 Cortical haemorrhage 
G611.00 Internal capsule haemorrhage 
G612.00 Basal nucleus haemorrhage 
G613.00 Cerebellar haemorrhage 
G614.00 Pontine haemorrhage 
G615.00 Bulbar haemorrhage 
G616.00 External capsule haemorrhage 
G617.00 Intracerebral haemorrhage, intraventricular 
G618.00 Intracerebral haemorrhage, multiple localized 
G619.00 Lobar cerebral haemorrhage 
G61X.00 Intracerebral haemorrhage in hemisphere, unspecified 
G61X000 Left sided intracerebral haemorrhage, unspecified 
G61X100 Right sided intracerebral haemorrhage, unspecified 
G61z.00 Intracerebral haemorrhage NOS 
G681.00 Sequelae of intracerebral haemorrhage 
Gyu6200 [X]Other intracerebral haemorrhage 
Gyu6F00 [X]Intracerebral haemorrhage in hemisphere, unspecified 
7017000 Evacuation of subdural haematoma 
7034.00 Drainage of subdural space 
7034y00 Other specified drainage of subdural space 
7034z00 Drainage of subdural space NOS 
G621.00 Subdural haemorrhage - nontraumatic 
G622.00 Subdural haematoma - nontraumatic 
G623.00 Subdural haemorrhage NOS 
S62..13 Subdural haemorrhage following injury 
S622.00 Closed traumatic subdural haemorrhage 
S622000 Subdural h'ge inj no open intracranial wnd + unspec consc 
S622100 Subdural h'ge inj no open intracranial wound+no loss consc 
S622200 Subdural h'ge inj no open intracranial wound+<1hr loss consc 
S622300 Subdural h'ge inj no open intracran wnd+1-24hr loss consc 
S622400 Subdural h'ge inj no open intracranial wnd+>24 LOC +recovery 
S622500 Subdural h'ge inj no open intracran wnd+>24hr LOC -restored 
S622600 Subdural h'ge inj no open intracran wnd+LOC unspec duration 
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S622z00 Subdural h'ge inj no open intracran wound+concussion unspec 
S623.00 Open traumatic subdural haemorrhage 
S623000 Subdural h'ge inj + open intracranial wound + unspec consc 
S623100 Subdural h'ge inj + open intracranial wound+no loss consc 
S623200 Subdural h'ge inj + open intracranial wound+<1hr loss consc 
S623300 Subdural h'ge inj + open intracranial wnd+1-24hr loss consc 
S623400 Subdural h'ge inj + open intracran wound+>24hr LOC +recovery 
S623500 Subdural h'ge inj + open intracran wnd+>24hr LOC -restored 
S623600 Subdural h'ge inj + open intracran wnd+LOC unspec duration 
S623z00 Subdural h'ge inj + open intracranial wnd+concussion unspec 
S628.00 Traumatic subdural haemorrhage 
S629.00 Traumatic subdural haematoma 
S629000 Traumatic subdural haematoma without open intracranial wound 
S629100 Traumatic subdural haematoma with open intracranial wound 
G60..00 Subarachnoid haemorrhage 
G601.00 Subarachnoid haemorrhage from carotid siphon and bifurcation 
G602.00 Subarachnoid haemorrhage from middle cerebral artery 
G603.00 Subarachnoid haemorrhage from anterior communicating artery 
G604.00 Subarachnoid haemorrhage from posterior communicating artery 
G605.00 Subarachnoid haemorrhage from basilar artery 
G606.00 Subarachnoid haemorrhage from vertebral artery 
G60X.00 Subarachnoid haemorrh from intracranial artery, unspecif 
G60z.00 Subarachnoid haemorrhage NOS 
G680.00 Sequelae of subarachnoid haemorrhage 
Gyu6000 [X]Subarachnoid haemorrhage from other intracranial arteries 
Gyu6100 [X]Other subarachnoid haemorrhage 
Gyu6E00 [X]Subarachnoid haemorrh from intracranial artery, unspecif 
S62..12 Subarachnoid haemorrhage following injury 
S620.00 Closed traumatic subarachnoid haemorrhage 
S620000 Subarachnoid h'ge inj no open intracran wound + unspec consc 
S620100 Subarachnoid h'ge inj no open intracran wnd+no loss consc 
S620200 Subarachnoid h'ge inj no open intracran wnd+<1hr loss consc 
S620300 Subarachnoid h'ge inj no open intracran wound + 1-24hr LOC 
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S620400 Subarachnoid h'ge inj no open intracran wnd+>24 LOC+recovery 
S620500 Subarach h'ge inj no open intracran wnd+>24hrs LOC-restored 
S620600 Subarach h'ge inj no open intracran wnd+LOC unspec duration 
S620z00 Subarach h'ge inj no open intracran wnd + concussion unspec 
S621.00 Open traumatic subarachnoid haemorrhage 
S621000 Subarachnoid h'ge inj + open intracran wound + unspec consc 
S621100 Subarachnoid h'ge inj + open intracranial wound + no LOC 
S621200 Subarachnoid h'ge inj + open intracran wound+<1hr loss consc 
S621300 Subarachnoid h'ge inj + open intracran wnd+1-24hr loss consc 
S621400 Subarach h'ge inj + open intracran wnd +>24hr LOC + recovery 
S621500 Subarach h'ge inj + open intracran wnd+>24hr LOC -restored 
S621600 Subarach h'ge inj + open intracran wnd+LOC unspec duration 
S621z00 Subarachnoid h'ge inj + open intracran wnd+concussion unspec 
S627.00 Traumatic subarachnoid haemorrhage 
7032000 Evacuation of extradural haematoma 
G600.00 Ruptured berry aneurysm 
G62..00 Other and unspecified intracranial haemorrhage 
G620.00 Extradural haemorrhage - nontraumatic 
G62z.00 Intracranial haemorrhage NOS 
G682.00 Sequelae of other nontraumatic intracranial haemorrhage 
Gyu6B00 [X]Sequelae of other nontraumatic intracranial haemorrhage 
S62..00 Cerebral haemorrhage following injury 
S62..11 Extradural haemorrhage following injury 
S62..14 Traumatic cerebral haemorrhage 
S620.11 Middle meningeal haemmorhage following injury 
S624.00 Closed traumatic extradural haemorrhage 
S624.11 Epidural haematoma following injury 
S624000 Extradural h'ge inj no open intracranial wnd + unspec consc 
S624100 Extradural h'ge inj no open intracranial wnd + no loss consc 
S624200 Extradural h'ge inj no open intracranial wnd+<1hr loss consc 
S624300 Extradural h'ge inj no open intracran wnd+1-24hr loss consc 
S624400 Extradural h'ge inj no open intracran wnd+>24hr LOC+recovery 
S624500 Extradural h'ge inj no open intracran wnd+>24hr LOC-restored 
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S624600 Extradural h'ge inj no open intracra wnd+LOC unspec duration 
S624z00 Extradural h'ge inj no open intracran wnd+concussion unspec 
S625.00 Open traumatic extradural haemorrhage 
S625000 Extradural h'ge inj + open intracranial wnd + unspec consc 
S625100 Extradural h'ge inj + open intracranial wound+no loss consc 
S625200 Extradural h'ge inj + open intracranial wnd+<1hr loss consc 
S625300 Extradural h'ge inj + open intracran wnd+1-24hr loss consc 
S625400 Extradural h'ge inj + open intracran wnd+>24hr LOC+recovery 
S625500 Extradural h'ge inj + open intracran wnd+>24hr LOC -restored 
S625600 Extradural h'ge inj + open intracran wnd+LOC unspec duration 
S625z00 Extradural h'ge inj + open intracran wnd+concussion unspec 
S626.00 Epidural haemorrhage 
S62A.00 Traumatic extradural haematoma 
S62A000 Traumatic extradural haemat without open intracranial wound 
S62A100 Traumatic extradural haematoma with open intracranial wound 
S62z.00 Cerebral haemorrhage following injury NOS 
S63..00 Other cerebral haemorrhage following injury 
S630.00 Other cerebral h'ge after injury no open intracranial wound 
S630.11 Cerebral compression due to injury 
S630.12 Intracranial haematoma following injury 
S630000 Oth cerebral h'ge inj no open intracran wnd+unspec consc 
S630100 Oth cerebral h'ge inj no open intracranial wnd+no loss consc 
S630200 Oth cerebral h'ge inj no open intracran wnd+<1hr loss consc 
S630300 Oth cerebral h'ge inj no open intracran wnd+1-24hr LOC 
S630400 Oth cereb h'ge inj no open intracran wnd+>24hr LOC +recovery 
S630500 Oth cereb h'ge inj no open intracran wnd+>24hr LOC -restored 
S630600 Oth cereb h'ge inj no open intracran wnd+LOC unspec duration 
S630z00 Oth cereb h'ge inj no open intracran wnd+concussion unspec 
S631.00 Other cerebral h'ge after injury + open intracranial wound 
S631000 Oth cerebral h'ge inj + open intracran wnd + unspec consc 
S631100 Oth cerebral h'ge inj + open intracranial wnd+no loss consc 
S631200 Oth cerebral h'ge inj + open intracran wnd+<1hr loss consc 
S631300 Oth cerebral h'ge inj + open intracran wnd+1-24hr loss consc 
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S631400 Oth cereb h'ge inj + open intracran wnd+>24hr LOC + recovery 
S631500 Oth cereb h'ge inj + open intracran wnd+>24hr LOC -restored 
S631600 Oth cereb h'ge inj + open intracran wnd+LOC unspec duration 
S631z00 Oth cereb h'ge inj + open intracran wnd+concussion unspec 
S63z.00 Other cerebral haemorrhage following injury NOS 
Heart Failure 
14A6.00 H/O: heart failure  
14AM.00 H/O: Heart failure in last year  
1O1..00 Heart failure confirmed  
388D.00 New York Heart Assoc classification heart failure symptoms  
662f.00 New York Heart Association classification - class I  
662g.00 New York Heart Association classification - class II  
662h.00 New York Heart Association classification - class III  
662i.00 New York Heart Association classification - class IV  
662p.00 Heart failure 6 month review  
662T.00 Congestive heart failure monitoring  
662W.00 Heart failure annual review  
679X.00 Heart failure education  
67D4.00 Heart failure information given to patient  
8B29.00 Cardiac failure therapy  
8CL3.00 Heart failure care plan discussed with patient  
8H2S.00 Admit heart failure emergency  
8HBE.00 Heart failure follow-up  
8Hg8.00 Discharge from practice nurse heart failure clinic  
8HHb.00 Referral to heart failure nurse  
8HHz.00 Referral to heart failure exercise programme  
8Hk0.00 Referred to heart failure education group  
8HTL.00 Referral to heart failure clinic  
9N0k.00 Seen in heart failure clinic  
9N2p.00 Seen by community heart failure nurse  
9N4s.00 Did not attend practice nurse heart failure clinic  
9N6T.00 Referred by heart failure nurse specialist  
9Or..00 Heart failure monitoring administration  
29 
 
9Or0.00 Heart failure review completed  
9Or1.00 Heart failure monitoring telephone invite  
9Or2.00 Heart failure monitoring verbal invite  
9Or3.00 Heart failure monitoring first letter  
9Or4.00 Heart failure monitoring second letter  
9Or5.00 Heart failure monitoring third letter  
G232.00 Hypertensive heart&renal dis wth (congestive) heart failure  
G234.00 Hyperten heart&renal dis+both(congestv)heart and renal fail  
G1yz100 Rheumatic left ventricular failure  
G5y4z00 Post cardiac operation heart failure NOS  
G5yy900 Left ventricular systolic dysfunction  
G5yyA00 Left ventricular diastolic dysfunction  
L09y200 Cardiac failure following abortive pregnancy  
Q48y100 Congenital cardiac failure  
Q490.00 Neonatal cardiac failure  
SP08400 Heart transplant failure and rejection  
SP08500 Heart-lung transplant failure and rejection  
SP11100 Cardiac insufficiency as a complication of care  
SP11111 Heart failure as a complication of care  
G58..00 Heart failure 
G58..11 Cardiac failure 
G580.00 Congestive heart failure 
G580.11 Congestive cardiac failure 
G580.12 Right heart failure 
G580.13 Right ventricular failure 
G580.14 Biventricular failure 
G580000 Acute congestive heart failure 
G580100 Chronic congestive heart failure 
G580200 Decompensated cardiac failure 
G580300 Compensated cardiac failure 
G580400 Congestive heart failure due to valvular disease 
G581.00 Left ventricular failure 
G581.11 Asthma - cardiac 
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G581.12 Pulmonary oedema - acute 
G581.13 Impaired left ventricular function 
G581000 Acute left ventricular failure 
G582.00 Acute heart failure 
G583.00 Heart failure with normal ejection fraction 
G583.11 HFNEF - heart failure with normal ejection fraction 
G583.12 Heart failure with preserved ejection fraction 
G584.00 Right ventricular failure 
G58z.00 Heart failure NOS 
G58z.11 Weak heart 
G58z.12 Cardiac failure NOS 
Transient ischemic attack 
8HBJ.00 Stroke / transient ischaemic attack referral  
Fyu5500 [X]Other transnt cerebral ischaemic attacks+related syndroms  
G65..00 Transient cerebral ischaemia  
G65..11 Drop attack  
G65..12 Transient ischaemic attack  
G65..13 Vertebro-basilar insufficiency  
G650.00 Basilar artery syndrome  
G650.11 Insufficiency - basilar artery  
G651.00 Vertebral artery syndrome  
G651000 Vertebro-basilar artery syndrome  
G652.00 Subclavian steal syndrome  
G653.00 Carotid artery syndrome hemispheric  
G654.00 Multiple and bilateral precerebral artery syndromes  
G655.00 Transient global amnesia  
G656.00 Vertebrobasilar insufficiency  
G65y.00 Other transient cerebral ischaemia  
G65z.00 Transient cerebral ischaemia NOS  
G65z000 Impending cerebral ischaemia  
G65z100 Intermittent cerebral ischaemia  
G65zz00 Transient cerebral ischaemia NOS  
Coronary artery bypass graft 
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7922z00 Allograft replacement of coronary artery NOS 
7922300 Allograft replacement of four or more coronary arteries 
7922000 Allograft replacement of one coronary artery 
7922200 Allograft replacement of three coronary arteries 
7922100 Allograft replacement of two coronary arteries 
7921300 Autograft replacement of four of more coronary arteries NEC 
7921000 Autograft replacement of one coronary artery NEC 
7921200 Autograft replacement of three coronary arteries NEC 
7921100 Autograft replacement of two coronary arteries NEC 
7925z00 Connection of mammary artery to coronary artery NOS 
7925y00 Connection of mammary artery to coronary artery OS 
7926z00 Connection of other thoracic artery to coronary artery NOS 
7926y00 Connection of other thoracic artery to coronary artery OS 
792..11 Coronary artery bypass graft operations 
7926000 Double anastom thoracic arteries to coronary arteries NEC 
7925000 Double anastomosis of mammary arteries to coronary arteries 
7925100 Double implant of mammary arteries into coronary arteries 
7926100 Double implant thoracic arteries into coronary arteries NEC 
SP00300 Mechanical complication of coronary bypass 
7921z00 Other autograft replacement of coronary artery NOS 
7921y00 Other autograft replacement of coronary artery OS 
792D.00 Other bypass of coronary artery 
792Dz00 Other bypass of coronary artery NOS 
792C.00 Other replacement of coronary artery 
7922y00 Other specified allograft replacement of coronary artery 
792Dy00 Other specified other bypass of coronary artery 
7923y00 Other specified prosthetic replacement of coronary artery 
792Cy00 Other specified replacement of coronary artery 
7924y00 Other specified revision of bypass for coronary artery 
7928200 Percut translum balloon angioplasty bypass graft coronary a 
7923z00 Prosthetic replacement of coronary artery NOS 
7923300 Prosthetic replacement of four or more coronary arteries 
7923000 Prosthetic replacement of one coronary artery 
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7923200 Prosthetic replacement of three coronary arteries 
7923100 Prosthetic replacement of two coronary arteries 
792C000 Replacement of coronary arteries using multiple methods 
792Cz00 Replacement of coronary artery NOS 
7924z00 Revision of bypass for coronary artery NOS 
7924300 Revision of bypass for four or more coronary arteries 
7924000 Revision of bypass for one coronary artery 
7924200 Revision of bypass for three coronary arteries 
7924100 Revision of bypass for two coronary arteries 
7924400 Revision of connection of thoracic artery to coronary artery 
7920z00 Saphenous vein graft replacement coronary artery NOS 
7920y00 Saphenous vein graft replacement of coronary artery OS 
7920300 Saphenous vein graft replacement of four+ coronary arteries 
7920000 Saphenous vein graft replacement of one coronary artery 
7920200 Saphenous vein graft replacement of three coronary arteries 
7920100 Saphenous vein graft replacement of two coronary arteries 
7925200 Single anast mammary art to left ant descend coronary art 
7925300 Single anastomosis of mammary artery to coronary artery NEC 
7926200 Single anastomosis of thoracic artery to coronary artery NEC 
7925400 Single implantation of mammary artery into coronary artery 
7926300 Single implantation thoracic artery into coronary artery NEC 
7927200 Transection of muscle bridge of coronary artery 
7927300 Transposition of coronary artery NEC 
ZV45700 [V]Presence of aortocoronary bypass graft 
ZV45K00 [V]Presence of coronary artery bypass graft 
ZV45K00 [V]Presence of coronary artery bypass graft 
ZV45K11 [V]Presence of coronary artery bypass graft - CABG 
ZV45K11 [V]Presence of coronary artery bypass graft - CABG 
7925011 LIMA sequential anastomosis 
7925012 RIMA sequential anastomosis 
7925311 LIMA single anastomosis 
7925312 RIMA single anastomosis 
7935600 Perc trans three dimen electroanat mapping conduct sys heart 
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7927000 Repair of arteriovenous fistula of coronary artery 
7927100 Repair of aneurysm of coronary artery 
7927y00 Other specified other open operation on coronary artery 
7927z00 Other open operation on coronary artery NOS 
792B000 Endarterectomy of coronary artery NEC 
792B.00 Repair of coronary artery NEC 
792By00 Other specified repair of coronary artery 
792Bz00 Repair of coronary artery NOS 
792y.00 Other specified operations on coronary artery 
792z.00 Coronary artery operations NOS 
7927.00 Other open operations on coronary artery 
7927.00 Other open operations on coronary artery 
7924.00 Revision of bypass for coronary artery 
7923.00 Prosthetic replacement of coronary artery 
7923.11 Prosthetic bypass of coronary artery 
7921.00 Other autograft replacement of coronary artery 
7925.11 Creation of bypass from mammary artery to coronary artery 
7925.00 Connection of mammary artery to coronary artery 
7926.00 Connection of other thoracic artery to coronary artery 
7922.00 Allograft replacement of coronary artery 
Percutaneous coronary intervention 
7927500 Open angioplasty of coronary artery 
7928000 Percut transluminal balloon angioplasty one coronary artery 
7928.00 Transluminal balloon angioplasty of coronary artery 
7928100 Percut translum balloon angioplasty mult coronary arteries 
7928.11 Percutaneous balloon coronary angioplasty 
7928y00 Transluminal balloon angioplasty of coronary artery OS 
7928z00 Transluminal balloon angioplasty of coronary artery NOS 
7929000 Percutaneous transluminal laser coronary angioplasty 
7929.00 Other therapeutic transluminal operations on coronary artery 
7929100 Percut transluminal coronary thrombolysis with streptokinase 
7929111 Percut translum coronary thrombolytic therapy- streptokinase 
7929200 Percut translum inject therap subst to coronary artery NEC 
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7929300 Rotary blade coronary angioplasty 
7929400 Insertion of coronary artery stent 
7929y00 Other therapeutic transluminal op on coronary artery OS 
7929z00 Other therapeutic transluminal op on coronary artery NOS 
ZV45800 [V]Presence of coronary angioplasty implant and graft 
ZV45L00 [V]Status following coronary angioplasty NOS 
793G.00 Perc translumin balloon angioplasty stenting coronary artery 
793K.00 Transluminal operations internal mammary artery side branch 
7933.00 Transluminal heart assist operations 
7934.00 Other therapeutic transluminal operations on heart 
7935.00 Diagnostic transluminal operations on heart 
793Gy00 OS perc translumina balloon angioplast stenting coronary art 
793Gz00 Perc translum balloon angioplasty stenting coronary art NOS 
793Ky00 OS transluminal operations internal mammary art side branch 
793Kz00 Transluminal operations internal mammary art side branch NOS 
793G000 Perc translum ball angio insert 1-2 drug elut stents cor art 
793H000 Percutaneous transluminal balloon dilation cardiac conduit 
793K000 Translum occlusion left internal mammary artery side branch 
793G100 Perc tran ball angio ins 3 or more drug elut stents cor art 
793G200 Perc translum balloon angioplasty insert 1-2 stents cor art 
793G300 Percutaneous cor balloon angiop 3 more stents cor art NEC 
7934y00 Other therapeutic transluminal operation on heart OS 
7934z00 Other therapeutic transluminal operation on heart NOS 
7935y00 Other specified diagnostic transluminal operation on heart 
7935z00 Diagnostic transluminal operation on heart NOS 
7928300 Percut translum cutting balloon angioplasty coronary artery 
7929500 Insertion of drug-eluting coronary artery stent 
7929600 Percutaneous transluminal atherectomy of coronary artery 
7933000 Transluminal insertion of pulsation balloon into aorta 
7928200 Percut translum balloon angioplasty bypass graft coronary a 
Peripheral artery disease 
700.11 Aorto-iliac disease                                                         
G702.00 Extremity artery atheroma                                                   
35 
 
G702z00 Extremity artery atheroma NOS                                               
G73..11 Peripheral ischaemic vascular disease                                       
G73..12 Ischaemia of legs                                                           
G73..13 Peripheral ischaemia                                                        
G730100 Raynaud's phenomenon                                                        
G731000 Buerger's disease                                                           
G731100 Presenile gangrene                                                          
G732.00 Peripheral gangrene                                                         
G732000 Gangrene of toe                                                             
G732100 Gangrene of foot                                                            
G733.00 Ischaemic foot                                                              
G734.00 Peripheral arterial disease                                                 
G73y.00 Other specified peripheral vascular disease                                 
G73y000 Diabetic peripheral angiopathy                                              
G73y100 Peripheral angiopathic disease EC NOS                                       
G73yz00 Other specified peripheral vascular disease NOS                             
G73z.00 Peripheral vascular disease NOS                                             
G73z000 Intermittent claudication                                                   
G73z011 Claudication                                                                
G73z012 Vascular claudication                                                       
G73z100 Spasm of peripheral artery                                                  
G73zz00 Peripheral vascular disease NOS                                             
G74..00 Arterial embolism and thrombosis                                            
G74..11 Arterial embolus and thrombosis                                             
G74..12 Thrombosis - arterial                                                       
G74..13 Arterial embolic and thrombotic occlusion                                   
G740.12 Aortoiliac obstruction                                                      
G740.13 Leriche's syndrome                                                          
G742400 Embolism and thrombosis of the femoral artery                               
G742500 Embolism and thrombosis of the popliteal artery                             
G742600 Embolism and thrombosis of the anterior tibial artery                       
G742700 Embolism and thrombosis of the dorsalis pedis artery                        
G742800 Embolism and thrombosis of the posterior tibial artery                      
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G742900 Embolism and thrombosis of a leg artery NOS                                 
G742B00 Post radiological embolism of lower limb artery                             
G742z00 Peripheral arterial embolism and thrombosis NOS                             
G74y000 Embolism and/or thrombosis of the common iliac artery                       
G74y100 Embolism and/or thrombosis of the internal iliac artery                     
G74y200 Embolism and/or thrombosis of the external iliac artery                     
G74y300 Embolism and thrombosis of the iliac artery unspecified                     
G74z.00 Arterial embolism and thrombosis NOS                                        
G761.00 Stricture of artery                                                         
G765.00 Necrosis of artery                                                          
G76A.00 Arterial insufficiency                                                      
G76z.00 Disorders of arteries and arterioles NOS                                    
G76z000 Iliac artery occlusion                                                      
G76z100 Femoral artery occlusion                                                    
G76z200 Popliteal artery occlusion                                                  
G7y..00 Other specified arterial, arteriole or capillary disease                    
G7z..00 Arterial, arteriole and capillary diseases NOS                              
Rango 14NB.00 H/O: Peripheral vascular disease procedure                                  
2I16.00 O/E - gangrene                                                              
R054.00 [D]Gangrene                                                                 
R054200 [D]Gangrene of toe in diabetic                                              
R054300 [D]Widespdiabetic foot gangrene                                        
8HlP.00 Referred for peripheral artery disease assessment                           
7A12100 Bypass bifurc aorta by anastom aorta to femoral artery NEC                  
7A12300 Bypass bifurcation aorta by anastom aorta to iliac artery                   
7A4..00 Iliac and femoral artery operations                                         
7A41.00 Other bypass of iliac artery                                                
7A41.11 Other bypass of iliac artery by anastomosis                                 
7A41100 Bypass iliac artery by iliac/femoral artery anastomosis NEC                 
7A41200 Emerg bypass iliac artery by femoral/femoral art anast NEC                  
7A41300 Bypass iliac artery by femoral/femoral art anastomosis NEC                  
7A41500 Emerg bypass iliac artery by aorta/ext iliac art anast NEC                  
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7A41600 Emerg bypass leg artery by aorta/com fem art anastomosis NEC                
7A41700 Emerg bypass leg artery by aorta/deep fem anastomosis NEC                   
7A41800 Emerg bypass iliac artery by iliac/iliac art anastomosis NEC                
7A41900 Bypass common iliac artery by aorta/com iliac art anast NEC                 
7A41A00 Bypass iliac artery by aorta/ext iliac art anastomosis NEC                  
7A41B00 Bypass leg artery by aorta/com femoral art anastomosis NEC                  
7A41C00 Bypass leg artery by aorta/deep femoral art anastomosis NEC                 
7A41D00 Bypass iliac artery by iliac/iliac artery anastomosis NEC                   
7A41E00 Emergency bypass of iliac artery by unspecified anastomosis                 
7A41y00 Other specified other bypass of iliac artery                                
7A41z00 Other bypass of iliac artery NOS                                            
7A42.00 Reconstruction of iliac artery                                              
7A42.11 Reconstruction of common iliac artery                                       
7A42000 Endarterectomy and patch repair of iliac artery                             
7A42011 Endarterectomy and patch repair of common iliac artery                      
7A42100 Endarterectomy of iliac artery NEC                                          
7A42111 Endarterectomy of common iliac artery NEC                                   
7A42y00 Other specified reconstruction of iliac artery                              
7A42z00 Reconstruction of iliac artery NOS                                          
7A43.00 Other open operations on iliac artery                                       
7A43.11 Other open operations on common iliac artery                                
7A43000 Repair of iliac artery NEC                                                  
7A43011 Repair of common iliac artery NEC                                           
7A43100 Open embolectomy of iliac artery                                            
7A43111 Open embolectomy of common iliac artery                                     
7A43300 Open insertion of iliac artery stent                                        
7A43y00 Other specified other open operation on iliac artery                        
7A43z00 Other open operation on iliac artery NOS                                    
7A44.00 Transluminal operations on iliac artery                                     
7A44.11 Transluminal operations on common iliac artery                              
7A44000 Percutaneous transluminal angioplasty of iliac artery                       
7A44100 Percutaneous transluminal embolectomy of iliac artery                       
7A44200 Arteriography of iliac artery                                               
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7A44211 Arteriography of common iliac artery                                        
7A44300 Insertion of iliac artery stent                                             
7A44400 Percutaneous transluminal insertion of iliac artery stent                   
7A44y00 Other specified transluminal operation on iliac artery                      
7A44z00 Transluminal operation on iliac artery NOS                                  
7A47.00 Other emergency bypass of femoral artery or popliteal artery                
7A47.11 Other emerg bypass femoral or popliteal art by anastomosis                  
7A47.12 Other emergency bypass of common femoral artery                             
7A47.13 Other emergency bypass of deep femoral artery                               
7A47.14 Other emergency bypass of popliteal artery                                  
7A47.15 Other emergency bypass of superficial femoral artery                        
7A47.16 Other emergency bypass of femoral artery                                    
7A47100 Emerg bypass popliteal art by pop/pop art anast c prosth NEC                
7A47500 Emerg bypass popliteal art by pop/tib art anast c prosth NEC                
7A47700 Emerg bypass pop art by pop/tib art anast c vein graft NEC                  
7A47900 Emerg bypass popliteal art by pop/peron a anast c prosth NEC                
7A47C00 Emerg bypass femoral artery by fem/fem art anastomosis NEC                  
7A47D00 Emerg bypass popliteal artery by pop/fem art anastomosis NEC                
7A47y00 Other emergency bypass of femoral or popliteal artery OS                    
7A47z00 Other emergency bypass of femoral or popliteal artery NOS                   
7A48.00 Other bypass of femoral artery or popliteal artery                          
7A48.11 Other bypass of femoral or popliteal artery by anastomosis                  
7A48.12 Other bypass of common femoral artery                                       
7A48.13 Other bypass of deep femoral artery                                         
7A48.14 Other bypass of femoral artery                                              
7A48.15 Other bypass of popliteal artery                                            
7A48000 Bypass femoral artery by fem/pop art anast c prosthesis NEC                 
7A48100 Bypass popliteal artery by pop/pop a anast c prosthesis NEC                 
7A48200 Bypass femoral artery by fem/pop art anast c vein graft NEC                 
7A48300 Bypass popliteal artery by pop/pop a anast c vein graft NEC                 
7A48400 Bypass femoral artery by fem/tib art anast c prosthesis NEC                 
7A48500 Bypass popliteal artery by pop/tib a anast c prosthesis NEC                 
7A48600 Bypass femoral artery by fem/tib art anast c vein graft NEC                 
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7A48700 Bypass popliteal artery by pop/tib a anast c vein graft NEC                 
7A48800 Bypass femoral artery by fem/peron a anast c prosthesis NEC                 
7A48900 Bypass popliteal artery by pop/peron art anast c prosth NEC                 
7A48A00 Bypass femoral artery by fem/peron a anast c vein graft NEC                 
7A48B00 Bypass popliteal art by pop/peron art anast c vein graft NEC                
7A48C00 Bypass femoral artery by femoral/femoral art anastomosis NEC                
7A48D00 Bypass popliteal artery by pop/fem artery anastomosis NEC                   
7A48y00 Other bypass of femoral artery or popliteal artery OS                       
7A48z00 Other bypass of femoral artery or popliteal artery NOS                      
7A49.00 Reconstruction of femoral artery or popliteal artery                        
7A49.11 Reconstruction of common femoral artery                                     
7A49.12 Reconstruction of deep femoral artery                                       
7A49.13 Reconstruction of femoral artery                                            
7A49.14 Reconstruction of popliteal artery                                          
7A49.15 Reconstruction of superficial femoral artery                                
7A49000 Endarterectomy and patch repair of femoral artery                           
7A49100 Endarterectomy and patch repair of popliteal artery                         
7A49200 Endarterectomy of femoral artery NEC                                        
7A49300 Endarterectomy of popliteal artery NEC                                      
7A49400 Profundoplasty femoral artery & patch repair deep fem artery                
7A49500 Profundoplasty and patch repair of popliteal artery                         
7A49600 Profundoplasty of femoral artery NEC                                        
7A49700 Profundoplasty of popliteal artery NEC                                      
7A49800 Reconstruction of femoral artery with vein graft                            
7A49900 Reconstruction of popliteal artery with vein graft                          
7A49y00 Reconstruction of femoral or popliteal artery OS                            
7A49z00 Reconstruction of femoral or popliteal artery NOS                           
7A4A.00 Other open operations on femoral artery or popliteal artery                 
7A4A.11 Other open operations on common femoral artery                              
7A4A.12 Other open operations on deep femoral artery                                
7A4A.13 Other open operations on popliteal artery                                   
7A4A.14 Other open operations on superficial femoral artery                         
7A4A000 Repair of femoral artery NEC                                                
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7A4A100 Repair of popliteal artery NEC                                              
7A4A200 Open embolectomy of femoral artery                                          
7A4A211 Open thrombectomy of femoral artery                                         
7A4A300 Open embolectomy popliteal artery                                           
7A4A311 Open thrombectomy of popliteal artery                                       
7A4A600 Operation on popliteal artery NEC                                           
7A4A700 Repair of femoral artery with temporary silastic shunt                      
7A4A800 Repair of popliteal artery with temporary silastic shunt                    
7A4Ay00 Other open operation on femoral or popliteal artery OS                      
7A4Az00 Other open operation on femoral or popliteal artery NOS                     
7A4B.00 Transluminal operations on femoral or popliteal artery                      
7A4B.11 Transluminal procedure on common femoral artery                             
7A4B.12 Transluminal procedure on deep femoral artery                               
7A4B.13 Transluminal procedure on femoral artery                                    
7A4B.14 Transluminal procedure on popliteal artery                                  
7A4B.15 Transluminal procedure on superficial femoral artery                        
7A4B000 Percutaneous transluminal angioplasty of femoral artery                     
7A4B100 Percutaneous transluminal angioplasty of popliteal artery                   
7A4B200 Percutaneous transluminal embolectomy of femoral artery                     
7A4B300 Percutaneous transluminal embolectomy of popliteal artery                   
7A4B400 Percutaneous transluminal embolisation of femoral artery                    
7A4B500 Percutaneous transluminal embolisation of popliteal artery                  
7A4B900 Percutaneous transluminal insertion of stent femoral artery                 
7A4By00 Transluminal operation on femoral or popliteal artery OS                    
7A4Bz00 Transluminal operation on femoral or popliteal artery NOS                   
7A4y.00 Other specified operations on iliac and femoral artery                      
7A4z.00 Iliac and femoral artery operations NOS                                     
7A50100 Revision of reconstruction involving iliac artery                           
7A50200 Revision of reconstruction involving femoral artery                         
7A50300 Revision of reconstruction of popliteal artery                              
7A53400 Operation on aneurysm of artery NEC                                         
7A56.00 Other therapeutic transluminal operations on artery                         
7A56000 Percutaneous transluminal arterial thrombolysis reconstruct                 
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7A56100 Percutaneous transluminal stent reconstruction of artery                    
7A56400 Percutaneous transluminal balloon angioplasty of artery                     
7A56600 Percutaneous transluminal placement peripheral stent artery                 
7A56y00 Other specified other therapeutic transluminal operat artery                
7A56z00 Other therapeutic transluminal operations on artery NOS                     
7M1D300 Transluminal approach to organ through femoral artery                       
7M25M00 Deep circumflex iliac artery flap                                           
7N46000 [SO]Common iliac artery                                                     
7N46100 [SO]Internal iliac artery                                                   
7N46200 [SO]Common femoral artery                                                   
7N46300 [SO]Deep femoral artery                                                     
7N46311 [SO]Profunda femoris artery                                                 
7N46400 [SO]Superficial femoral artery                                              
7N46500 [SO]Popliteal artery                                                        
7N46600 [SO]Tibial artery                                                           
7N46700 [SO]External iliac artery                                                   
7N46800 [SO]Deep circumflex iliac artery                                            
7N46B00 [SO]Other artery of thigh                                                   
7N46C00 [SO]Anterior tibial artery                                                  
7N46D00 [SO]Posterior tibial artery                                                 
7N46F00 [SO]Medial plantar artery                                                   
7N46G00 [SO]Lateral plantar artery                                                  
7N46H00 [SO]Dorsalis pedis artery                                                   
7N46J00 [SO]Digital artery of toe                                                   
7NB8000 [SO]Anterior tibial artery                                                  
7NB8100 [SO]Posterior tibial artery                                                 
7NB8300 [SO]Dorsalis pedis artery                                                   
7NB8400 [SO]External iliac artery                                                   
7NB8500 [SO]Iliac artery NEC                                                        
7NB8600 [SO]Tibial artery NEC                                                       
F336.00 Phantom limb syndrome                                                       
F336000 Phantom limb syndrome with pain                                             
F336100 Phantom limb syndrome without pain                                          
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Table S3. Comparison of post-propensity match baseline characteristics between the US Truven MarketScan 
mortality subset and US Truven MarketScan total population 
 
US Truven MarketScan Mortality 
subset 
US Truven MarketScan Total data 
Difference 
Mortality vs Total 
SGLT-2i 
(N=71,632) 
oGLD 
(N=71,632) 
SGLT-2i 
(N=116,899) 
oGLD 
(N=116,899) 
SGLT-2i oGLD 
n % n % n % n % % % 
Age in years, 
mean (SD) 
55.8 (9.5) 56.0 (10.2) 55.76 (9.68) 55.79 (10.24) 
 
Women 31,715 44.3 32,151 44.9 53,293 45.6 53,806 46.0 -1.3 -1.1 
Frailty (yes) 2,869 4.0 3,295 4.6 5,340 4.6 5,382 4.6 -0.6 0.0 
Established CVD* 6,452 9.0 6,918 9.7 11,218 9.6 11,292 9.7 -0.6 0.0 
   Acute MI 576 0.8 630 0.9 1,052 0.9 1,036 0.9 -0.1 0.0 
   Unstable angina 711 1.0 756 1.1 1,222 1.0 1,227 1.0 0.0 0.1 
   Heart failure 1,638 2.3 1,845 2.6 3,025 2.6 3,039 2.6 -0.3 0.0 
   Atrial fibrillation 1,892 2.6 2,085 2.9 3,308 2.8 3,330 2.8 -0.2 0.1 
   Stroke 2,413 3.4 2,615 3.7 4,165 3.6 4,219 3.6 -0.2 0.1 
   PAD 1,835 2.6 1,884 2.6 3,119 2.7 3,128 2.7 -0.1 -0.1 
Microvascular 
disease 
18,673 26.1 18,896 26.4 31,454 26.9 31,548 27.0 -0.8 -0.6 
CKD 1,742 2.4 2,112 2.9 3,305 2.8 3,501 3.0 -0.4 -0.1 
Statin therapy 48,567 67.8 48,120 67.2 78,061 66.8 77,992 66.7 1.0 0.5 
Antihypertensive 
therapy 
59,172 82.6 58,711 82.0 95,336 81.6 95,247 81.5 1.0 0.5 
   Loop diuretics 5,581 7.8 5,768 8.1 9,504 8.1 9,452 8.1 -0.3 0.0 
Metformin 59,007 82.4 57,210 79.9 92,569 79.2 93,369 79.9 3.2 0.0 
SU 29,943 41.8 28,973 40.4 47,582 40.7 47,771 40.9 1.1 -0.5 
DPP-4 inhibitor 26,876 37.5 24,681 34.5 41,970 35.9 40,683 34.8 1.6 -0.3 
TZD 7,890 11.0 7,282 10.2 12,497 10.7 11,872 10.2 0.3 0.0 
GLP-1RA 14,880 20.8 11,916 16.6 23,513 20.1 19,843 17.0 0.7 -0.4 
Insulin 21,548 30.1 20,411 28.5 34,844 29.8 34,251 29.3 0.3 -0.8 
Index year: 
   2013 9,266 12.9 12,811 17.9 16,426 14.1 21,068 18.0 -1.2 -0.1 
   2014 34,832 48.6 27,152 37.9 58,305 49.9 46,303 39.6 -1.3 -1.7 
   2015 27,534 38.4 31,669 44.2 42,168 36.1 49,528 42.4 2.3 1.8 
Index medication: 
Amylin analog NA NA 78 0.10 NA NA 132 0.10 
 
0.0 
Metformin NA NA 8,335 11.6 NA NA 13,624 11.7 
 
-0.1 
SU NA NA 12,781 17.8 NA NA 20,725 17.7 
 
0.1 
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DPP-4i NA NA 11,525 16.1 NA NA 18,350 15.7 
 
0.4 
TZD NA NA 4,200 5.9 NA NA 6,954 5.9 
 
0.0 
GLP-1RA NA NA 9,940 13.9 NA NA 16,337 14.0 
 
-0.1 
Insulin NA NA 23,438 32.7 NA NA 38,529 33.0 
 
-0.3 
Meglitinides NA NA 986 1.4 NA NA 1,623 1.4 
 
0.0 
Acarbose, NA NA 349 0.5 NA NA 625 0.5 
 
0.0 
Dapagliflozin 16,091 22.5 NA NA 25,940 0.222 NA NA 0.3 
 
Empagliflozin 5,783 8.1 NA NA 9,097 0.078 NA NA 0.3 
 
Canagliflozin 49,758 69.5 NA NA 81,862 0.7 NA NA -0.5 
 
 
*Defined as myocardial infarction, unstable angina, stroke, heart failure, transient ischemic attack, coronary 
revascularization (coronary artery bypass grafting or percutaneous coronary intervention) or occlusive peripheral artery 
disease on or ever prior to start; CKD=chronic kidney disease; CVD=cardiovascular disease; DPP-4=dipeptidyl peptidase-4; 
oGLD=other glucose-lowering drug; GLP-1RA= Glucagon-like peptide-1 receptor agonists; MI=myocardial infarction; 
NA=not applicable; PAD=peripheral arterial disease; SGLT-2i=sodium-glucose cotransporter-2 inhibitor; SU=sulfonylurea; 
TZD=thiazolidinedione; US=United States  
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Table S4. List of variables used to develop propensity score 
Gender 
Age 
Race (Caucasian, Black, Asian, Other) 
Migrant 
Frailty (yes) 
Index year 
Duration of Type 2 diabetes (years) 
Cardiovascular history 
Smoker 
HbA1c >7% (UK only) 
Body mass index ≥30 kg/m2 (UK only) 
Duration of Type 2 diabetes 
Estimated Glomerular Filtration Rate <60 mL/min/1.73 m2  (UK only) 
Acute myocardial infarction  
Stroke 
Heart failure 
Unstable angina 
Atrial fibrillation 
Peripheral artery disease 
Hypertension 
Coronary revascularization 
Coronary artery bypass grafting 
Percutaneous coronary intervention 
Carotid intervention 
Chronic kidney disease 
Microvascular disease 
Nephropathy 
Peripheral neuropathy 
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Retinopathy 
Bariatric surgery 
Metformin 
Sulfonylurea 
DPP-4 inhibitor 
thiazolidinedione 
GLP-1 receptor agonist 
Insulin 
Statin therapy 
Antihypertensive therapy 
P2Y12 inhibitiors 
Antiplatelets 
Warfarin 
Anticoagulants 
Low dose acetylsalicylic acid 
Beta-blocker 
Loop diuretics 
Thiazides 
Aldosterone antagonists 
Weight loss drugs 
DPP-4=dipeptidyl peptidase-4; GLP-1= Glucagon-like peptide-1. 
The full list of variables for each individual country is dependent on the variables available in each database 
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Table S5. Baseline characteristics for all countries/databases pre-match 
 
US Truven MarketScan Norway national registers Denmark national registers Sweden national registers UK CPRD/THIN Germany DPV 
SGLT-2i 
N=123,648 
oGLD 
N=712,426 
SGLT-2i 
N=14,438 
oGLD 
N=96,947 
SGLT-2i 
N=9522 
oGLD 
N=119,137 
SGLT-2i 
N=9337 
oGLD 
N=200,284 
SGLT-2i 
N=7556 
oGLD 
N=73,436 
SGLT-2i 
N=1532 
oGLD 
N=23,991 
Age, years, mean  55.7 58.1 59.7 61.2 60.3 62.3 61.4 65.4 58.5 63.6 61.5 69.5 
Women 45.5 46.7 39.4 43.6 39.5 44.6 37.7 42.5 41.2 42.8 42.0 47.6 
Established CVD* 9.5 15.3 19.3 22.4 29.6  32.0 24.5 30.3 15.2 22.1 35.1 48.2 
   Acute MI 0.9 1.9 5.9 6.6 7.6 8.4 9.4 10.4  5.9 8.2 10.0 11.1 
   Unstable angina 1.0 1.5 3.4 3.0 3.5 3.5 4.8 4.7 1.5  1.7 3.4 5.3 
   HF 2.5 6.1 4.1 6.9 3.9 5.3 6.2 9.8 2.3  5.1 5.3 9.4 
   AF 2.8 5.5 6.1 9.3 5.6 7.7 7.5 11.6 3.7 7.7 5.2 8.2 
   Stroke 3.5 6.1 2.9 4.4  7.2  9.5 5.3 8.7 3.1 5.5  5.3  9.3 
   PAD 2.6 3.9 5.6 6.5 5.0  6.4 4.7 5.8 3.0 4.3 21.5 31.5 
Microvascular    
disease 
27.2 23.6 31.2 22.6 34.9  19.0 13.7 12.0 34.4  23.4 50.8  49.5 
CKD 2.7† 5.9† 1.5 5.5 0.5 2.5 0.9 3.5 0.7† 2.3† 19.6 46.5 
Frailty(yes) 4.4 11.5 11.3 21.7 30.9  31.3 11.5 22.2 17.2‡ 22.7‡ 19.8 47.7 
Glucose-lowering therapies 
   MET 80.2 41.5 70.6 35.3  78.9  36.2 80.2 37.4 90.5 51.1 71.3 45.3 
   SU 41.2 22.9 36.8 15.0 28.4  12.6 23.2 11.9 51.6 27.0 10.1 14.5 
   DPP-4i 36.9 13.1 22.4 6.1 20.8  4.6 25.4 5.1 44.1 10.9 31.2 20.4 
   TZD 11.1 4.9 2.3 0.6  0.5  0.1 3.2 0.6 10.7 5.7 4.8 0.9 
   GLP-1RA 22.4 4.6 15.8 2.5 35.3  5.0 21.6 2.2 22.9 3.2 17.5 4.0 
   Insulin 30.8 17.2 19.0 18.4  28.7  16.5 44.4 25.1 21.6 5.1 48.4 61.8 
Cardiovascular therapies 
   Antihypertensive 81.8 77.3 69.9 62.2 79.1  64.5 79.4 72.2 75.7 73.6 65.3 56.7 
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therapies§ 
   Loop diuretics 8.1 11.5 10.1 15.0 13.5  18.2 15.2 18.5 11.6 14.1 5.2 7.1 
   Thiazide diuretics – – 1.9 2.4  16.3  15.0 7.4 8.0 17.5 18.1 27.7 30.0 
Statin therapy 67.2 58.7 62.4 49.4  75.6 52.1 68.6 53.5 82.1 73.4 39.4 29.8 
Index year 
   2012 
   2013 
   2014 
   2015 
   2016 
 
– 
13.5 
49.1 
37.4 
– 
 
– 
38.2 
39.5 
22.4 
– 
 
– 
9.0 
32.7 
35.6 
22.7 
 
– 
24.8 
28.4 
30.1 
16.7 
 
 0.2 
 20.1 
31.4 
48.2 
– 
 
2.8 
 31.7 
 31.1 
 34.5 
– 
 
– 
8.2 
33.4 
58.5 
– 
 
– 
16.8 
38.5 
44.8 
– 
 
0 
11.9 
41.8 
45.9 
0.4 
 
6.74 
38.1 
31.8 
23.1 
0.2 
 
0.07 
10.5 
24.0 
33.5 
32.0 
 
21.8 
38.5 
 19.2 
 13.7 
 6.8 
Data are % unless otherwise stated; *Defined as myocardial infarction, unstable angina, stroke, heart failure, transient ischemic attack, coronary revascularization (coronary artery bypass grafting or percutaneous 
coronary intervention) or occlusive peripheral artery disease on or ever prior to start †CKD in the indicated database does not include end stage renal disease; ‡Frailty in the indicated database is defined as ≥1 
hospitalization within 1 year prior to or on index date; §Includes angiotensin converting enzyme inhibitors, angiotensin receptor blockers, Ca2+ channel blockers  β-blockers, thiazides; AF=atrial fibrillation; 
CKD=chronic kidney disease; CPRD, Clinical Practice Research Datalink; CVD=cardiovascular disease; DPP-4i=dipeptidyl peptidase-4 inhibitor; DPV, Diabetes Patientenverlaufsdokumentation; eGFR=estimated 
Glomerular Filtration Rate; HF=heart failure; oGLD=other glucose-lowering drug; GLP-1RA= Glucagon-like peptide-1 receptor agonists; MET=metformin; MI, myocardial infarction; PAD=peripheral arterial disease; 
SGLT-2i=sodium-glucose cotransporter-2 inhibitor; SU=sulfonylurea; THIN, The Health Improvement Network; TZD, thiazolidinedione  
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Table S6. Baseline characteristics for all countries/databases post-match 
 
US Truven MarketScan Norway national registers Denmark national registers Sweden national registers UK CPRD/THIN Germany DPV 
SGLT-2i 
N=116,899 
oGLD 
N=116,899 
SGLT-2i 
N=12,525 
oGLD 
N=12,525 
SGLT-2i 
N=9234 
oGLD 
N=9234 
SGLT-2i 
N=9189 
oGLD 
N=9189 
SGLT-2i 
N=5231 
oGLD 
N=5231 
SGLT-2i 
N=1450 
oGLD 
N=1450 
Age, years, mean 
(SD) 
55.8 (9.7) 55.8 (10.2) 60.4 (11.3) 60.3 (12.7) 60.4 (10.8) 60.9 (12.4) 61.5 (10.2) 61.4 (11.5) 58.8 (10.5) 58.8 (10.8) 61.7 (11.2) 61.7 (11.7) 
Women 45.6 46.0 41.4 39.8 39.7 39.8 37.8 37.8 41.9 42.4 42.7 42.3 
Established CVD* 9.6 9.7 20.0 20.4 29.6 30.4 24.5 24.6 15.7 16.2 35.5 37.1 
   Acute MI 0.9 0.9 5.9 6.1 7.7 8.0 9.3 9.3 5.6 6.4 9.8 10.3 
   Unstable angina 1.0 1.0 3.4 3.4 3.4 3.7 4.7 4.7 1.4 1.6 3.6 3.8 
   HF 2.6 2.6 4.4 4.4 3.9 4.2 6.2 6.2 2.4 2.5 5.5 5.7 
   AF 2.8 2.8 6.6 6.7 5.7 5.9 7.5 7.7 4.1 3.6 5.2 5.5 
   Stroke 3.6 3.6 4.6 4.4 7.3 7.5 7.3 7.2 3.3 3.7 5.6 5.9 
   PAD 2.7 2.7 5.9 5.8 5.1 5.3 4.8 4.6 3.0 2.8 21.7 21.3 
   Microvascular 
disease 
26.9 27.0 31.4 32.0 34.3 33.0 13.5 12.8 32.5 32.4 49.7 51.6 
   CKD 2.8† 3.0† 1.8 1.7 0.5 0.4 0.9 0.8 0.8† 0.8† 19.5 28.4 
Frailty(yes) 4.6 4.6 12.2 12.9 30.7 30.7 11.6 11.7 17.5‡ 20.5‡ 20.0 51.7 
Glucose-lowering therapies 
MET 79.2 79.9 69.2 73.4 78.3 81.4 80.0 82.8 88.9 89.8 71.2 72.1 
SU 40.7 40.9 34.4 34.2 28.0 29.2 23.0 24.1 50.9 51.4 10.3 9.6 
DPP-4i 35.9 34.8 21.0 21.5 20.1 19.3 25.0 24.9 41.8 41.1 31.6 33.2 
TZD 10.7 10.2 2.1 2.0 – – 3.0 2.6 10.8 10.8 3.4 3.1 
GLP-1RA 20.1 17.0 13.6 12.7 33.6 31.0 20.6 18.3 17.4 17.2 16.0 15.2 
Insulin 29.8 29.3 20.0 21.6 27.8 28.6 43.8 42.7 17.5 16.6 49.3 48.6 
Cardiovascular therapies 
Antihypertensive 
therapy§ 
81.6 81.5 70.9 70.8 78.9 78.5 79.6 79.7 75.4 75.4 64.5 65.0 
   Loop diuretics 8.1 8.1 11.0 11.3 13.6 14.1 15.2 14.9 12.8 13.2 5.2 5.5 
  Thiazide diuretics 33.1 33.1 2.0 2.1 16.3 16.3 7.4 7.6 16.9 16.9 27.9 28.5 
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   ACE inhibitors 46.6 46.6 18.9 19.8 39.7 40.6 36.5 36.6 49.0 49.7 30.0 32.0 
   ARBs 30.0 29.8 45.3 44.6 34.8 35.1 38.2 38.4 19.5 18.9 19.2 15.8 
Statin therapy 66.8 66.7 62.4 62.6 75.3 77.8 68.4 68.5 82.1 81.2 38.3 38.8 
Aspirin NA NA 38.1 37.9 37.4 38.4 34.6 34.4 31.2 32.4 18.3 19.5 
Index year 
   2012 
   2013 
   2014 
   2015 
   2016 
 
– 
14.1 
49.9 
36.1 
– 
 
– 
18.0 
39.6 
42.4 
– 
 
– 
10.0 
32.9 
35.1 
21.9 
 
– 
9.9 
32.5 
35.3 
22.4 
 
0.2 
20.6 
31.6 
47.5 
– 
 
1.2 
20.0 
29.8 
48.9 
– 
 
– 
8.2 
33.5 
58.3 
– 
 
– 
7.9 
34.0 
 58.1 
– 
 
0 
15.0 
43.6 
41.2 
0.2 
 
1.6 
13.1 
44.1 
41.0 
0.3 
 
0.1 
10.8 
24.8 
33.9 
30.5 
 
5.1 
10.6 
16.1 
38.0 
30.3 
Data are % unless otherwise stated; *Defined as myocardial infarction, unstable angina, stroke, heart failure, transient ischemic attack, coronary revascularization (coronary artery bypass grafting or percutaneous 
coronary intervention) or occlusive peripheral artery disease on or ever prior to start †CKD in the indicated database does not include end stage renal disease; ‡Frailty in the indicated database is defined as ≥1 
hospitalization within 1 year prior to or on index date; §Includes ACE inhibitors, ARBs, Ca2+ channel blockers  β-blockers, thiazides; ACE=angiotensin converting enzyme; ARB=angiotensin receptor blocker; 
AF=atrial fibrillation; CKD=chronic kidney disease; CPRD, Clinical Practice Research Datalink; CV=cardiovascular; CVD=cardiovascular disease; DPP-4i=dipeptidyl peptidase-4 inhibitor; DPV, Diabetes 
Patientenverlaufsdokumentation; eGFR=estimated Glomerular Filtration Rate; HF=heart failure; oGLD=other glucose-lowering drug; GLP-1RA= Glucagon-like peptide-1 receptor agonists; MET=metformin; MI, 
myocardial infarction; PAD=peripheral arterial disease; SGLT-2i=sodium-glucose cotransporter-2 inhibitor; SU=sulfonylurea; THIN, The Health Improvement Network; TZD, thiazolidinedione  
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Table S7. Standardized differences in baseline characteristics between SGLT-2i and oGLD treatment groups pre- and post-propensity match by country 
 
Standardized Difference (%) 
US Truven MarketScan 
(N=233,798) 
Norway national registers 
(N=25,050) 
Denmark national registers 
(N=18,468) 
Sweden national 
registers (N=18,378) 
UK CPRD/THIN  
(N=10,462) 
Germany DPV  
(N=2900) 
Pre-match  Post-match  Pre-match  Post-match  Pre-match  Post-match  Pre-match  Post-match  Pre-match  Post-match  Pre-match  Post-match  
Age 21.1 0.3 11.3 0.8 15.3 4.3 33.2 0.6 43.1 0 27.2 0.1 
Women 2.4 0.9 6.8 2.6 8.5 0.2 7.9 0 3.4 1.0 4.3 0.2 
Established CVD* NA NA 6.0 0.8 4.3 1.4 10.4 0.1 17.7 1.5 10.4 0.9 
   Acute MI 8.7 0.1 2.4 0.7 2.4 0.9 2.9 0.1 8.9 3.6 1.3 0.4 
   Unstable angina 4.5 0 2.0 0.1 0 1.3 0.2 0 2.0 1.7 4.0 0.3 
   Heart failure 17.5 0.1 9.8 0.3 5.6 1.3 10.5 0.2 14.9 0.1 6.8 0.2 
   Stroke 11.9 0.2 6.3 0.9 6.9 0.6 10.7 0.9 12.0 2.0 6.7 0.3 
   PAD 6.8 0 3.1 0.4 5.0 0.7 3.8 0.5 6.6 1.0 9.2 0.3 
   Coronary 
revascularization 
NA NA 2.0 0.7 NA NA NA NA 6.6 2.2 2.6 0.1 
      CABG 5.8 0.1 0.7 0.9 NA NA 0.9 0.4 5.6 0.1 NA NA 
      PCI 3.1 0.2 2.0 1.3 NA NA 2.9 0.3 3.3 1.9 NA NA 
      Carotid 
intervention 
2.3 0.1 NA NA NA NA NA NA 4.3 NA 0.4 0.4 
   Atrial fibrillation 13.5 0.1 9.6 0.6 7.1 0.7 11.0 0.6 17.3 2.3 4.9 0.2 
Microvascular 
disease 
NA NA 16.2 0.9 28.8 2.2 4.1 1.8 24.3 0 1.0 1.0 
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CKD† 15.5 1.0 16.3 0.4 15.3 1.2 13.2 1.4 12.7 0 NA NA 
Frailty(yes)‡ 26.4 0.2 22.2 1.6 0.7 0 22.7 0.3 13.8 7.7 26.2 18.9 
Migrant NA NA NA NA NA NA NA NA NA NA 8.0 0.6 
Smoker (yes) 6.5 0.6 NA NA NA NA NA NA 3.6 0.1 4.3 2.0 
HbA1c (mean) NA NA NA NA NA NA NA NA 19.1 11.0 7.3 3.1 
HbA1c >7% NA NA NA NA NA NA NA NA 39.1 1.5 10.15 1.8 
BMI (mean) NA NA NA NA NA NA NA NA 42.4 10.9 14.55 2.35 
BMI≥30 NA NA NA NA NA NA NA NA 44.6 1.3 14.8 4.6 
Total cholesterol NA NA NA NA NA NA NA NA 14.8 0 5.3 2.1 
eGFR (mean) NA NA NA NA NA NA NA NA 24.2 10.9 27.1 5.0 
eGFR <60 NA NA NA NA NA NA NA NA 46.8 0.1 25.2 5.7 
Nephropathy 3.6 0.5 NA NA NA NA NA NA 0.1 0.3 NA NA 
Peripheral 
neuropathy 
6.1 0.1 NA NA NA NA NA NA 6.4 0.8 5.1 0.5 
Retinopathy 7.4 0.1 NA NA NA NA NA NA 23.8 0.1 0.2 0.5 
Hypertension 9.4 0 NA NA NA NA NA NA 1.0 2.1 NA NA 
Microalbuminuria NA NA NA NA NA NA NA NA NA NA 0.4 0.4 
Weight-loss drugs 8.2 0.8 3.2 0.4 2.1 0 6.3 0.4 7.1 0.9 1.2 0 
Bariatric surgery NA NA NA NA NA NA 1.7 0.2 4.5 2.9 2.1 0 
Time from start NA NA NA NA NA NA NA NA 90.9 0 55.2 0.6 
T2D duration NA NA 67.4 1.7 9.4 15.5 77.9 1.6 43.8 1.7 8.9 0.4 
Glucose-lowering therapies 
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   Metformin 86.2 1.7 61.3 7.7 80.4 6.3 76.5 6.0 96.0 2.7 21.7 0.5 
   Sulfonylurea 40.0 0.3 44.2 0.5 31.1 2.2 76.5 2.0 52.1 1.1 5.5 0.6 
   DPP-4 inhibitor 57.1 2.3 43.1 1.0 37.5 1.6 25.6 0.1 79.9 1.4 8.9 0.9 
   TZD 22.9 1.8 13.0 0.7 NA NA 17.9 2.1 18.0 0.1 NA NA 
   GLP-1 RA 54.2 8.1 44.3 2.3 60.3 4.5 59.8 4.8 61.3 0.6 13.8 0.6 
   Insulin 32.3 1.1 1.1 3.2 23.3 1.5 34.6 1.8 49.8 2.3 10.2 0.4 
Cardiovascular therapies 
   Antihypertensive 
therapy§ 
11.0 0.2 13.2 0.3 27.6 0.8 14.2 0.1 5.0 0 6.9 0.3 
   Loop diuretics 11.8 0.2 11.8 0.9 10.7 1.2 7.1 0.7 7.5 1.1 3.1 0.3 
   Thiazide diuretics 5.1 0 2.7 0.5 2.9 0 1.7 0.8 1.7 0.1 1.9 0.3 
   β-blocker 6.7 0.3 0.5 1.3 0.9 1.6 2.8 0.5 9.4 0.2 1.0 1.2 
   Statin therapy 17.8 0.1 21.4 0.3 42.3 4.8 25.2 0.2 21.1 2.2 7.4 0.2 
   Aspirin NA NA 7.2 0.4 13.6 1.7 5.6 0.4 2.1 2.5 0.2 0.8 
   PY12 inhibitors NA NA 0.6 0.4 3.5 0.7 1.0 NA NA 0.8 1.9 0.5 
   Antiplatelets 6.0 0.2 NA NA NA NA NA NA 0.2 2.1 NA NA 
   Warfarin NA NA 10.1 0.8 8.3 1.2 8.1 0.7 13.4 2.5 1.6 0.7 
   Anticoagulants 10.6 0.3 NA NA NA NA NA NA 14.2 1.8 NA NA 
   Aldosterone 
antagonists 
3.2 0 2.0 0.4 2.2 1.1 0.8 0.5 8.2 1.0 3.4 0.7 
*Defined as myocardial infarction, unstable angina, stroke, heart failure, transient ischemic attack, coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention) or occlusive 
peripheral artery disease on or ever prior to start ; †CKD in UK CPRD/THIN and US Truven MarketScan does not include end stage renal disease; ‡Frailty in UK CPRD/THIN is defined as ≥1 hospitalization within 1 
year prior to index date;§Includes angiotensin converting enzyme inhibitors, angiotensin receptor blockers, Ca2+ channel blockers  β-blockers, thiazides; BMI=body mass index; CABG=Coronary artery bypass 
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grafting; CKD=chronic kidney disease; CPRD, Clinical Practice Research Datalink; CV=cardiovascular; DPP-4=dipeptidyl peptidase-4; DPV=Diabetes Patientenverlaufsdokumentation; eGFR=estimated Glomerular 
Filtration Rate; GLP-1RA= Glucagon-like peptide-1 receptor agonist; MI=myocardial infarction; OAD=oral antidiabetic drugs; PAD=peripheral arterial disease; PCI=percutaneous coronary intervention; T2D=Type 2 
diabetes; THIN=The Health Improvement Network; TZD=thiazolidinedione; UK=United Kingdom; US=United States; NA=not applicable (some characteristics were not available in every country)  
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Table S8. Composition of SGLT-2 inhibitor class in propensity matched cohorts 
 SGLT-2 
inhibitor 
patients, N 
Proportions by agent 
Canagliflozin, % Dapagliflozin, % Empagliflozin, % 
Hospitalization for heart failure analysis 
US Truven MarketScan 
 
116,899 70 22 8 
Norway national registers 12,525 0 83 17 
Denmark national registers 9234 4 79 17 
Sweden national registers 9189 0 83 17 
UK CPRD/THIN 5231 2 86 12 
Germany DPV 1450 2 64 33 
Total 154,528 53 37 10 
All-cause death analysis, and composite (HHF or all-cause death) analysis  
US Truven MarketScan 
 
71,632 69 22 8 
Norway national registers 12,525  0 83 17 
Denmark national registers 9234 4 79 17 
Sweden national registers 9189 0 83 17 
UK CPRD/THIN 5231 2 86 12 
Total 107,811  47  43   11 
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Table S9. Index glucose-lowering medication classes for patients in the other GLD group: all countries 
combined (HHF analysis) 
Variable 
Other GLD 
(N=154,528) 
Index medication*, n (%) 
   MET 
   SU 
   DPP-4 inhibitor 
   TZD 
   GLP-1 receptor agonist 
   Insulin   
   Acarbose 
Amylin analog  
Meglitinides 
 
17,899 (11.6) 
26,203 (17.0) 
26,957 (17.4) 
7496 (4.9) 
21,199 (13.7) 
51,838 (33.5) 
708 (0.5) 
132 (0.1) 
2096 (1.4) 
*In cases of ≥2 medications, one was randomly selected; DPP-4=dipeptidyl peptidase-4; GLD=glucose-lowering drug; GLP-
1= Glucagon-like peptide-1; HHF=hospitalization for heart failure; MET=metformin; SU=sulfonylurea; TZD= thiazolidinedione 
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Table S10. Index glucose-lowering medication classes for patients in the other GLD group: all countries 
combined (all-cause death analysis and HHF or all-cause death analysis) 
Variable 
Other GLD 
(N=107,811) 
Index medication*, n (%) 
   MET 
   SU 
   DPP-4 inhibitor 
   TZD 
   GLP-1 receptor agonist 
   Insulin   
   Acarbose 
Amylin analog  
Meglitinides 
 
12,134 (11.3) 
18,203 (16.9) 
19,665 (18.2) 
4731 (4.4) 
14,743 (13.7) 
36,432 (33.8) 
424 (0.4) 
78 (0.1) 
1401 (1.3) 
*In cases of ≥2 medications, one was randomly selected; DPP-4=dipeptidyl peptidase-4; GLD=glucose-lowering drug; GLP-
1= Glucagon-like peptide-1; HHF=hospitalization for heart failure; MET=metformin; SU=sulfonylurea; TZD= thiazolidinedione 
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Table S11: Number of patients, person-years at risk (on treatment), events and events/100 person-years 
(incidence rates) for each of the endpoints 
Country/database Patients, N Person-years Events, n Events /  
100 person-
years 
Hospitalization for heart failure 
   US Truven  
   MarketScan 
233,798 125,904 298 0.24 
   Norway national  
   registers 
25,050 25,166 278 1.10 
   Denmark national  
   registers 
18,468 17,159 167 0.97 
   Sweden national  
   registers 
18,378 13,688 191 1.40 
   UK CPRD/THIN 10,462 6833 16 0.23 
   Germany DPV 2900 1414 11 0.78 
   Total 309,056 190,164 961 0.51 
All-cause death 
   US Truven  
   MarketScan 
143,264 80,556 250 0.31 
   Norway national  
   registers 
25,050 25,368 364 1.43 
   Denmark national  
   registers 
18,468 17,267 323 1.87 
   Sweden national  
   registers 
18,378 23,946 317 1.32 
   UK CPRD/THIN 10,462 6853 80 1.17 
   Total 215,622 153,990 1334 0.87 
Composite of hospitalization for heart failure or all-cause death 
   US Truven  
   MarketScan 
143,264 80,496 424 0.53 
   Norway national  
   registers 
25,050 25,166 622 2.47 
   Denmark national  
   registers 
18,468 17,159 477 2.78 
   Sweden national  
   registers 
18,378 13,688 364 2.66 
   UK CPRD/THIN 10,462 6833 96 1.40 
   Total 215,622 143,342 1983 1.38 
CPRD= Clinical Practice Research Datalink; DPV= Diabetes Patientenverlaufsdokumentation; SGLT-2=sodium-glucose cotransporter-2; 
THIN=The Health Improvement Network; UK=United Kingdom; US=United States   
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Table S12. Pooled event rates by treatment groups 
 
SGLT-2i oGLD 
 
Events Person-years 
Events/100 
person-years 
Events Person-years 
Events/100 
person-years 
Hospitalization for 
heart failure 
367 100,952 0.36 594 89,212 0.67 
All-cause death 412 79,888 0.52 922 74,102 1.24 
Hospitalization for 
heart failure  and all-
cause death 
667 74,665 0.89 1316 68,677 1.92 
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Table S13. Mean on treatment follow-up time (in days) by country and endpoint 
 HHF ACD HHF/ACD 
 SGLT-2i oGLD SGLT-2i oGLD SGLT-2i oGLD 
US MarketScan/Truven 217 176 225 186 225 186 
UK-CPRD/THIN 225 252 226 253 225 252 
Sweden 261 283 463 489 261 283 
Norway 364 370 366 374 364 370 
Denmark 328 351 330 353 328 351 
Germany 236 124     
Total 239 211 271 251 253 233 
ACD=all-cause death; HHF=hospitalization for heart failure; oGLD=other glucose-lowering drug; SGLT-
2i=sodium-glucose cotransporter-2 
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Table S14. Sensitivity analyses examining association between treatment with SGLT-2i vs. oGLD and 
outcomes of HHF in Sweden, among patients with both in- and outpatient hospital visits with primary 
diagnosis of heart failure, and those with only inpatient hospital visits with the primary diagnosis of 
heart failure.  
 oGLD 
Events, n (events/100PY) 
SGLT-2i 
Events, n (events/100PY) 
Hazard 
ratio 
95% CI P-value 
On treatment, both in- and 
outpatient 
122 (17.1) 69 (10.5) 0.61 0.45-0.82 0.001 
On treatment, only inpatient 70 (9.8) 30 (4.6) 0.46 0.30-0.71 <0.001 
ITT, both in- and outpatient 150 (17.1) 101 (12.3) 0.72 0.56-0.93 0.012 
ITT, only inpatient 89 (10.1) 49 (5.9) 0.59 0.42-0.84 0.003 
CI=confidence interval; HHF=hospitalization for heart failure; oGLD=other glucose-lowering drug; PY=person-
years; SGLT-2i=sodium-glucose cotransporter-2. 
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SUPPLEMENTARY FIGURES 
 
Figure S1: Patient selection flow-charts for each country  
A. US Truven MarketScan  
 
 
B. Norway National Registers 
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C. Denmark National Registers 
 
 
D. Sweden National Registers 
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E. UK CPRD/THIN 
 
 
F. Germany DPV 
 
CPRD=Clinical Practice Research Datalink; DPV= Diabetes Patientenverlaufsdokumentation; GLD=glucose-lowering drugs;  
HHF=hospitalization for heart failure; SGLT-2i=sodium-glucose cotransporter-2 inhibitors; THIN=The Health Improvement Network; 
UK=United Kingdom; US=United States  
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Figure S2: Propensity score distribution by country pre-match 
A 
 
B 
 
C 
 
D 
 
E 
 
F 
 
CPRD=Clinical Practice Research Datalink; DPV=Diabetes Patientenverlaufsdokumentation; SGLT-2=sodium-glucose 
cotransporter-2; THIN=The Health Improvement Network; UK=United Kingdom; US=United States  
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Figure S3: Propensity score distribution by country post-match 
A 
 
B 
 
C 
 
D 
 
E 
 
F 
 
CPRD=Clinical Practice Research Datalink; DPV=Diabetes Patientenverlaufsdokumentation; SGLT-2=sodium-glucose 
cotransporter-2; THIN=The Health Improvement Network; UK=United Kingdom; US=United States 
  
67 
 
Figure S4: Standardized difference between SGLT-2 inhibitor and other GLD treatment groups by country 
 
A. US Truven MarketScan 
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B. Norway National Registers 
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C. Denmark National Registers 
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D. Sweden National Registers 
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E. UK CPRD/THIN 
 
72 
 
 
 
 
 
 
 
 
 
 
73 
 
 
 
 
F. Germany DPV 
 
DPP-4=dipeptidyl peptidase-4; eGFR=estimated Glomerular Filtration Rate; GLP-1= Glucagon-like peptide-1; 
oGLD=other glucose-lowering drug; SGLT-2i=sodium-glucose cotransporter -2 inhibitor; T2D=Type 2 diabetes  
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Figure S5: Stepwise sensitivity analysis (sequentially removing comparators): Outcome of hospitalization for  
heart failure 
 
A. On treatment, adjusted* – TZD removed 
 
 
*Adjusted for history of heart failure, age, gender, frailty, history of myocardial infarction, history of atrial 
fibrillation, hypertension, obesity / body mass index, duration of diabetes, ACE inhibitor or ARB use; β-blocker or 
α-blocker use, Ca+-channel blocker use, loop diuretic use, thiazide diuretic use; TZD=thiazolidinedione  
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B. On treatment, adjusted* – TZD and insulin removed 
 
 
*Adjusted for history of heart failure, age, gender, frailty, history of myocardial infarction, history of atrial 
fibrillation, hypertension, obesity / body mass index, duration of diabetes, ACE inhibitor or ARB use; β-blocker or 
α-blocker use, Ca+-channel blocker use, loop diuretic use, thiazide diuretic use; TZD= thiazolidinedione   
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C. On treatment, adjusted* – TZD, insulin and SU removed 
 
 
*Adjusted for history of heart failure, age, gender, frailty, history of myocardial infarction, history of atrial 
fibrillation, hypertension, obesity / body mass index, duration of diabetes, ACE inhibitor or ARB use; β-blocker or 
α-blocker use, Ca+-channel blocker use, loop diuretic use, thiazide diuretic use; SU=sulfonylurea; TZD= 
thiazolidinedione 
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Figure S6: Outcome of hospitalization for heart failure excluding patients with baseline GLP-1 RAs, on treatment, 
adjusted* 
 
 
*Adjusted for history of heart failure, age, gender, frailty, history of myocardial infarction, history of atrial 
fibrillation, hypertension, obesity / body mass index, duration of diabetes, ACE inhibitor or ARB use; β-blocker or 
α-blocker use, Ca+-channel blocker use, loop diuretic use, thiazide diuretic use; SU=sulfonylurea; TZD= 
thiazolidinedione 
Data from Germany and UK not included as they contributed too few HHF events after removal of GLP1-RA 
class 
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Figure S7: Outcomes for hospitalization for heart failure, all-cause death, and hospitalization for heart failure or all-cause 
death for the SGLT-2 inhibitor versus other GLD treatment groups   
 
A. US only 
 
 
B. European countries combined 
  
 
P-value for SGLT-2i versus oGLD comparison <0.001 for all endpoints; oGLD=other glucose-lowering drug;  
79 
 
SGLT-2i=sodium-glucose cotransporter-2; US=United States     
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